Document:

<Page>

                                                                    Exhibit 10.9

                                    AGREEMENT
This Agreement (AGREEMENT) is entered into as of June 29, 2001 (EFFECTIVE DATE)
between NeoGenesis Drug Discovery, Inc., a Delaware corporation (NEOGENESIS) and
Biogen, Inc. (CUSTOMER), a Massachusetts corporation, and sets forth the terms
and conditions that will apply to the provision by NeoGenesis to CUSTOMER of
certain screening and analysis services.

                                   BACKGROUND

         CUSTOMER is interested in identifying potential pharmaceutical products
for treatment of human diseases and wishes to identify compounds that exhibit a
high degree of chemical binding and functional activity to specific protein
targets. NeoGenesis owns or controls certain technology and know-how, including
screening processes of libraries of mass-encoded small molecule compounds,
relating to the identification, discovery, validation and optimization of novel
compounds which may be useful for development of novel therapeutics employing
targets implicated in a disease process. The parties wish to pursue a
collaborative screening process to identify compounds exhibiting a high degree
of chemical binding activity to targets designated by CUSTOMER from among the
NeoGenesis libraries, or from CUSTOMER libraries, of mass-encoded small molecule
compounds and which have activity in target-specific functional assays. The
terms and conditions set forth below shall govern the performance of such
collaborative effort.

1.   DEFINITIONS.

1.1 DEFINED TERMS. Capitalized terms used in this Agreement and not otherwise
defined herein shall have the meaning set forth below.

     AFFILIATE means with respect to either party, any Person that, directly or
indirectly, is controlled by, controls or is under common control with such
party. For purposes of this definition, CONTROL means, with respect to any
Person, the direct or indirect ownership of [*] or more of the voting or income
interest in such Person or the possession otherwise, directly or indirectly, of
the power to direct the management or policies of such Person.

     ALIS means the Automated Ligand Identification System, an automated,
ultra-high throughput ligand selection system proprietary to NeoGenesis that is
used to identify multiple classes of chemical ligands against target protein.

     APPLICABLE LAWS means all laws, statutes, regulations and ordinances of any
Regulatory Authority, including without limitation the FD&C Act.

     CHEMOTYPE means a family or group of structurally-related Primary Active
Compounds (as defined in ATTACHMENT A).

     CIP means "Carriage and Insurance Paid", as that expression is defined in
INCOTERMS 2000, ICC Publishing S.A.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       1
<Page>

     COMBINATION PRODUCT means a product which includes one or more active
ingredients or active components other than Licensed Product in combination with
Licensed Product.

     COMMERCIALLY REASONABLE EFFORTS means, with respect to (i) any objective by
any party, reasonable, diligent, good faith efforts to accomplish such objective
as such party would normally use to accomplish a similar objective under similar
circumstances; and (ii) with respect to any objective relating to the
development or Commercialization of any Licensed Product by any party, efforts
and resources normally used by such party with respect to a product owned by
such party or to which such party has similar rights which is of similar market
potential at a similar stage in the development or life of such product, taking
into account issues of safety, efficacy, product profile, the competitiveness of
the marketplace, the proprietary position of the product, the regulatory
structure involved, profitability of the product and other relevant technical
and/or commercial factors.

     COMMERCIALIZATION means any and all activities of using, importing,
exporting, marketing, promoting, distributing, offering for sale and selling a
Licensed Product. When used as a verb, COMMERCIALIZE means to engage in
Commercialization. Commercialization does not include any activities of CUSTOMER
or its Affiliates or sublicensees within the R&D Program or reasonably related
to obtaining Regulatory Approval.

     CONFIDENTIAL INFORMATION means any proprietary or confidential information
of either party (including but not limited to all CUSTOMER Know-How and all
NeoGenesis Know-How) disclosed to the other party pursuant to this Agreement,
except any portion thereof which: (i) is known to the receiving party, as
evidenced by the receiving party's written records, before receipt thereof under
this Agreement; (ii) is disclosed to the receiving party by a third person who
is under no obligation of confidentiality to the disclosing party hereunder with
respect to such information and who otherwise has a right to make such
disclosure; (iii) is or becomes generally known in the trade through no fault of
the receiving party; or (iv) is independently developed by the receiving party
before receipt thereof under this Agreement, as evidenced by the receiving
party's written records, without access to such information.

     CONTROL OR CONTROLLED means with respect to any (a) item of information,
including, without limitation, CUSTOMER Know-How and NeoGenesis Know-How, or (b)
intellectual property right, the possession (whether by ownership or license,
other than pursuant to this Agreement) by a party or an Affiliate thereof of the
ability to grant to the other party access or a license as provided herein under
such item or right without violating the terms of any agreement or other
arrangements, between such party or its Affiliate and any third party, existing
before or after the Effective Date.

     CUSTOMER KNOW-HOW means all proprietary technical, Manufacturing and
clinical information, data and know-how, including but not limited to all
Program Intellectual Property described in clause (c) of the definition of
Program Intellectual Property, relating to: (a) the Targets, ligands, assays, or
libraries provided by CUSTOMER, (b) the Designated Compounds, together with,
where applicable, any analogs, derivatives, fragments, sub-cellular constituents
or

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       2
<Page>

expression products thereof, or (c) the Licensed Products, whether or not
patentable, Controlled by CUSTOMER or its Affiliates or sublicensees as of the
Effective Date or during the term of this Agreement. CUSTOMER Know-How includes,
without limitation, all processes, formulas, discoveries and inventions whether
relating to biological, chemical, pharmacological, toxicological,
pharmaceutical, physical and analytical safety, quality control and clinical
data, including, without limitation, clinical study data. CUSTOMER Know-How also
includes relevant medical information relating to the Licensed Products (such as
customer questions, responses thereto and adverse drug event history) in the
possession of CUSTOMER, its Affiliates or sublicensees. The term CUSTOMER
Know-How, however, does not include the NeoGenesis Know-How or any know-how,
processes, information and data which is, as of the Effective Date or later
becomes, through no fault of NeoGenesis, generally available to the public.

     CUSTOMER PATENT RIGHTS means (a) those patents and patent applications
(other than patent applications and patents included within the NeoGenesis
Patent Rights) Controlled by CUSTOMER or any of its Affiliates at any time
during the term of this Agreement which otherwise would be infringed by the
research, development, manufacture, use, importation or sale or offer for sale
of any Designated Compound or Licensed Product and (b) all divisionals,
continuations, continuations-in-part, reissues, extensions, supplementary
protection certificates and foreign counterparts thereof.

     FDA means the United States Food and Drug Administration, or any successor
thereto.

     FD&C ACT means the United States Federal Food, Drug and Cosmetic Act of
1938, as amended.

     FIELD means the diagnosis, prevention and/or treatment of any and all
diseases in humans.

     FIRST COMMERCIAL SALE of Licensed Product(s) means any transfer for value
in an arms-length transaction to an independent third party distributor, agent
or end user in a country within the Territory after obtaining all necessary
Regulatory Approvals as may be necessary for such transfer in such country.

     FORCE MAJEURE means any event beyond the control of the parties, including,
without limitation, failures of computers, computer-related equipment, hardware
or software, fire, flood, riots, strikes, epidemics, war (declared or undeclared
and including the continuance, expansion or new outbreak of any war or conflict
now in existence), embargoes and governmental actions or decrees.

     FTE means the equivalent of a full time (twelve months, including normal
vacations, sick days and holidays) work of a person, carried out by one or more
employees or agents of NeoGenesis, who devotes a portion of his or her time to
performing further optimization activities as set forth in this Agreement, such
amount per FTE not to exceed [*] for the Program services specified in
paragraphs 1-7 and 9 of ATTACHMENT A (i.e., optimization of three Selected
Compounds to a Kd value of [*] and one round of optimization on [*] Selected
Compounds);

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       3
<Page>

and not to exceed [*] for Program services beyond those specified in paragraphs
1-7 and 9 of ATTACHMENT A.

     GOOD CLINICAL PRACTICE means the then current standards for clinical trials
for pharmaceuticals, as set forth in the FD&C Act and applicable regulations
promulgated thereunder, as amended from time to time, and such standards of good
clinical practice as are required by the European Union and other Regulatory
Authorities in countries in which Licensed Product is intended to be sold, to
the extent such standards are not in contravention with United States Good
Clinical Practices.

     GOOD LABORATORY PRACTICE means the then current standards for laboratory
activities for pharmaceuticals, as set forth in the FD&C Act and applicable
regulations promulgated thereunder, as amended from time to time, and such
standards of good laboratory practice as are required by the European Union and
other Regulatory Authorities in countries in which Licensed Product is intended
to be sold, to the extent such standards are not in contravention with United
States Good Laboratory Practices.

     GOOD MANUFACTURING PRACTICE means the current standards for the manufacture
of pharmaceuticals, as set forth in the FD&C Act and applicable regulations
promulgated thereunder, as amended from time to time, and such standards of good
manufacturing practice as are required by the European Union and other
Regulatory Authorities in countries in which Licensed Product is intended to be
sold, to the extent such standards are not in contravention with United States
Good Manufacturing Practices.

     IND means an investigational new drug application, as defined in the FD&C
Act and applicable regulations thereunder, or any equivalent document, filed
with the FDA and necessary for beginning clinical trials of any Licensed Product
in humans or any equivalent application or other documentation filed with any
Regulatory Authority of a country other than the United States prior to
beginning clinical trials of any Licensed Product in humans in that country.

     LICENSED PRODUCT(S) means any product that: (a) includes a Designated
Compound or any derivatives, improvements and components thereof; and (b) the
development, manufacture, use, or sale of which, absent the license granted
under this Agreement, would infringe the NeoGenesis Know-How or NeoGenesis
Patent Rights or which makes use of any Program Intellectual Property that is
jointly owned by the parties.

     MAJOR COUNTRY means the United States, the United Kingdom, France, Germany,
Italy or Japan, as the case may be.

     MANUFACTURING means any and all activities involved in the production of a
Licensed Product to be developed and/or Commercialized under this Agreement.
When used as a verb, MANUFACTURE means to engage in Manufacturing.

     NDA means a new drug application as defined in the FD&C Act and applicable
regulations thereunder, and the foreign equivalent thereof.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       4
<Page>

     NEOGENESIS KNOW-HOW means all proprietary technical information, data and
know-how, including but not limited to all Program Intellectual Property
described in clause (a) of the definition of Program Intellectual Property,
relating to: (a) the NeoMorph Screening Library, (b) the NeoMorph Focused
Libraries, (c) ALIS and QSCD, (d) the Preliminary Compounds, (e) the Primary
Active Compounds, (f) the Selected Compounds, together with, where applicable,
any analogs, derivatives, fragments, sub-cellular constituents or expression
products thereof made by NeoGenesis, and (g) any other tangible materials
provided by NeoGenesis to CUSTOMER for use in the conduct of the Program(s),
which in each case is Controlled by NeoGenesis or any of its Affiliates as of
the date of this Agreement or at any time during the term of this Agreement. The
term NeoGenesis Know-How, however, does not include (1) any CUSTOMER Know-How or
compound, (2) any know-how, processes, information and data which is, as of the
Effective Date or later becomes, generally available to the public or (3) any
general manufacturing or other know-how not specific to the Designated Compound
or Licensed Products.

     NEOGENESIS PATENT RIGHTS means those (a) all patent applications (including
provisional, utility, international and design applications) (including
NeoGenesis' interest in Program Patent Rights) heretofore or hereafter filed in
any country covering the NeoGenesis Know-How which but for the licenses granted
pursuant to this Agreement would be infringed by the development, manufacture,
use, offer for sale, sale or import of Designated Compounds or Licensed
Products; (b) all patents from the applications identified in clause (a) that
have issued or in the future issue from any of the foregoing patent
applications, including without limitation utility models, design patents and
certificates of invention; and (c) all divisionals, continuations,
continuations-in-part, reissues, extensions, supplementary protection
certificates and foreign counterparts of the applications and patents identified
in clauses (a)-(b), in each case which are Controlled by NeoGenesis or any of
its Affiliates and are existing as of the Effective Date or filed or issued
during the term of this Agreement.

     NEOMORPH CHEMISTRY means the process, proprietary to NeoGenesis, of forming
libraries and sub-libraries of discrete compounds by coupling a broad set of
diverse cores with diverse sets of building blocks employing proprietary
mass-coding algorithms.

     NEOMORPH FOCUSED LIBRARIES means those compounds synthesized by NeoGenesis
derived from Primary Active Compounds identified by CUSTOMER in bioassays or
functional assays.

     NEOMORPH SCREENING LIBRARY means the entire collection of libraries
consisting of mass-encoded small molecule organic compounds owned by NeoGenesis
and developed with NeoMorph Chemistry, comprising at least 10,000,000 different
compounds.

     NET SALES means the aggregate amounts invoiced for sales or transfers for
value of Licensed Products by CUSTOMER, its Affiliates or any of its
sublicensees to an independent third party distributor, agent or end user in the
Territory (other than sales of Licensed Products at cost by CUSTOMER, its
Affiliates or sublicensees to a third party for use in a clinical study prior to
Regulatory Approval of such Licensed Product) LESS deductions selected as
appropriate from: (a) credits, refunds, allowances and price adjustments
separately and actually credited to

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       5
<Page>

customers for defective, spoiled, damaged, outdated, and returned Licensed
Products, (b) offered and taken trade and cash discounts, rebates, chargebacks
and allowances in amounts customary to the trade, (c) sales, excise, value
added, turnover, use, and other like taxes, and customs duties, paid, absorbed
or allowed excluding net income tax, (d) allowances for bad debt in accordance
with U.S. Generally Accepted Accounting Principles (GAAP) consistently applied,
and (e) special outbound packing, transportation, insurance and handling charges
separately billed to the customer or prepaid. Net Sales shall not include
amounts received by CUSTOMER (or any of its Affiliates) from transactions with
an Affiliate or sublicensee, where the Licensed Product in question will be
resold by such Affiliate or sublicensee to an independent third-party
distributor, agent or end user and such amounts received by the Affiliate or
sublicensee from such resale is included in Net Sales in accordance with Section
4.3.

                  For purposes of this Agreement, "sale" means any transfer or
other distribution or disposition, but shall not include transfers or other
distributions or dispositions of Product, at no charge, for preclinical,
clinical or regulatory purposes or in connection with patient assistance
programs or other charitable purposes or to physicians or hospitals for
promotional purposes. Product shall be considered "sold" when billed or
invoiced.

                  In the event that Licensed Product is sold in the form of a
Combination Product, Net Sales for the Combination Product shall be determined
by multiplying actual Net Sales of the Combination Product (determined by
reference to the definition of Net Sales set forth above) during the royalty
payment period by the fraction A/A+B where A is the average sale price of
Licensed Product when sold separately in finished form and B is the average
sales price of the other active ingredients and components when sold separately
in finished form, in each case during the applicable royalty payment period in
the country in which the sale of the Combination Product was made, or if sales
of both the Licensed Product and the other active ingredients and components did
not occur in such period, then in the most recent royalty payment period in
which sales of both occurred. Where the Licensed Product is sold separately in
finished form but the other ingredients and components are not, Net Sales for
the Combination Product shall be determined by multiplying actual Net Sales of
the Combination Product (determined by reference to the definition of Net Sales
set forth above) during the royalty payment period by the ratio of the average
per-unit sale price of Licensed Product when sold separately in finished form to
the average per-unit Net Sales of the Combination Product, in each case during
the applicable royalty payment period in the country in which the sale of the
Combination Product was made. Where the other active ingredients and components
are sold separately in finished form but the Licensed Product is not, Net Sales
for the Combination Product shall be determined by multiplying actual Net Sales
of the Combination Product (determined by reference to the definition of Net
Sales set forth above) during the royalty payment period by the difference
obtained by subtracting from 1 the ratio of the average per-unit sale price of
the other active ingredients and components when sold separated in finished form
to the average per-unit Net Sales of the Combination Product, in each case
during the applicable royalty reporting period in the country in which the sale
of the Combination Product was made. In the event that such average sales price
cannot be determined for either of the Licensed Product or for all other active
ingredients and components included in the Combination Product, Net Sales for
purposes of determining payments under this Agreement shall be calculated by
multiplying the Net Sales of the Combination Product by the fraction

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       6
<Page>

C/C+D where C is the standard fully-absorbed cost of the Licensed Product
portion of the Combination Product and D is the sum of the standard
fully-absorbed costs of all other active ingredients and components included
in the Licensed Product, in each case as determined in accordance with GAAP
consistently applied; provided, however that the parties mutually agree that
such approach is valid in light of the particular circumstances, which
agreement shall not be unreasonably withheld or delayed.

     PATENT RIGHTS means all U.S. and foreign issued patents and patent
applications, including but not limited to provisionals, divisionals,
continuations, continuations-in-part, and patents issuing therefrom, reissues,
reexaminations, substitutions, renewals, restorations, additions, registrations,
and foreign counterparts thereof, as well as extensions and supplementary
protection certificates based thereon.

     PERSON means any individual, corporation, association, partnership (general
or limited), joint venture, trust, estate, limited liability company, limited
liability partnership, unincorporated organization, government (or any agency or
political subdivision thereof) or other legal entity or organization.

     PROGRAM means the program(s) described in ATTACHMENT A as the same may be
amended during the term of this Agreement by mutual agreement of the parties
acting through the Steering Committee (as defined below). Each Program will be
directed toward the discovery and development of Primary Active Compounds and
Selected Compounds for a particular Target.

     PROGRAM INTELLECTUAL PROPERTY means individually and collectively all
discoveries, inventions, know-how, techniques, methodologies, modifications,
improvements, works of authorship, designs and data (whether or not protectable
under patent, copyright, trade secrecy or similar laws) that are conceived,
created, discovered, developed, or reduced to practice or tangible medium of
expression (a) solely by one or more employees or consultants of NeoGenesis
(other than consultants also affiliated with CUSTOMER in connection with the
Program) at any time in the course of the Program; (b) jointly by one or more
employees or consultants of NeoGenesis and one or more employees or consultants
of CUSTOMER at any time in the course of the Program; or (c) solely by one or
more employees or consultants of CUSTOMER (other than consultants also
affiliated with NeoGenesis in connection with the Program) at any time in the
course of the Program.

     PROGRAM PATENT RIGHTS shall mean, collectively, (a) all patent applications
hereafter filed in any country which specifically claim and only to the extent
they claim Program Intellectual Property; (b) all patents that have issued or in
the future issue from any of the foregoing patent applications, including
without limitation utility models, design patents and certificates of invention;
and (c) all divisionals, continuations, continuations-in-part, reissues,
renewals, extensions, supplementary protection certificates or additions to any
such patents and patent applications.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       7
<Page>

     QSCD means Quantized Surface Complimentary Diversity, a model proprietary
to NeoGenesis, in terms of which discrete chemical compliments to the surfaces
of a target are defined.

     R&D PROGRAM means on a Designated Compound-by-Designated Compound and
country-by-country basis the activities necessary or desirable to be undertaken
in connection with the research and development of such Designated Compound
prior to obtaining Regulatory Approval for a Licensed Product in such country
(regardless of the country in which such activities are conducted).

     REGULATORY APPROVALS means, for any country in the Territory, those
authorizations by the appropriate Regulatory Authority(ies) required for the
manufacture, importation, marketing, promotion, pricing and sale of the Licensed
Product(s) in such country.

     REGULATORY AUTHORITY means any national, supra-national, regional, state or
local regulatory agency, department, bureau, commission, council or other
governmental entity in the Territory, including, without limitation, the FDA.

     SAMPLE means any compound or mixture of compounds supplied by CUSTOMER to
NeoGenesis for the purpose of ALIS screening under activities in Attachment A,
PARA. 10.

     SOP means a standard operating procedure which is optimized for ALIS
screening of a given CUSTOMER Target.

     TARGET means a specific protein target(s) selected by CUSTOMER for which
NeoGenesis will perform the Program. CUSTOMER shall have the right to designate
up to four Targets (which for purposes hereof shall not include Targets which
are unavailable or are rejected by NeoGenesis because of their unavailability)
during the term of this Agreement. The Target(s) will be added to ATTACHMENT B
as and when designated by CUSTOMER.

     TERRITORY means all the countries of the world.

     VALID CLAIM means a claim of a Patent Right that has not been canceled,
withdrawn, or rejected and has not elapsed or become abandoned or declared
invalid or unenforceable or been revoked by a court or agency of competent
jurisdiction from which no appeal can be or has been taken and, with respect to
a claim of a patent application within Patent Rights, has not been pending for
more than ten years.

1.2  OTHER DEFINED TERMS.  The following terms shall have the meanings set forth
     in the section appearing opposite such term:

<Table>
         <S>                                         <C>
         BANKRUPTCY CODE                             Section 3.1
         CLAIM NOTICE                                Section 6.6
         COMPONENT                                   ATTACHMENT A
         COMPOUNDS                                   ATTACHMENT A

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       8
<Page>

         DESIGNATED COMPOUND                         Section 2.6
         DISCRETE COMPOUND                           ATTACHMENT A
         GENERIC PATENT RIGHTS                       Section 3.3
         ICC                                         Section 9.1
         INDEMNIFYING PARTY                          Section 7.4
         INDEMNIFIED PARTY(IES)                      Section 7.3
         IPO                                         Section 4.8
         FINAL TARGET REPORT                         ATTACHMENT A
         LICENSED TECHNOLOGY                         Section 3.1
         LOSSES                                      Section 7.2
         PHASE II CLINICAL TRIALS                    Section 4.2
         PMA                                         Section 4.2
         PRELIMINARY COMPOUND                        ATTACHMENT A
         PRELIMINARY SAMPLE                          ATTACHMENT A
         PRIMARY ACTIVE COMPOUNDS                    ATTACHMENT A
         PRIMARY ACTIVE COMPOUNDS REPORT             ATTACHMENT A
         SCREENING PERIOD                            Section 2.2
         SELECTED COMPOUND(S)                        ATTACHMENT A
         STEERING COMMITTEE                          Section 2.5
</Table>

2.   SCREENING PROGRAM; R&D PROGRAM; COMMERCIALIZATION

2.1  DELIVERY OF TARGET PROTEINS. CUSTOMER shall have up to [*] following the
Effective Date to designate and deliver up to [*] Targets to NeoGenesis for
screening. CUSTOMER shall provide Targets in the quantities and formats
specified in ATTACHMENT A. CUSTOMER shall also provide NeoGenesis at the time of
delivery with a written description of the concentration and volume of the
Target. CUSTOMER shall deliver the Targets CIP to NeoGenesis's Cambridge, MA
facility.

2.2  SCREENING PROGRAM. The parties agree that the first Target shall be TGF
beta receptor Type I. Upon designation of any additional Target by CUSTOMER,
NeoGenesis will have [*] to agree to conduct the control and follow up control
experiments of para. 2 of ATTACHMENT A with that Target or to reject (because of
its unavailability) the Target. Upon such agreement, CUSTOMER shall within [*]
deliver all necessary reagents with respect to such Target to NeoGenesis.
NeoGenesis shall within [*] of receipt of such reagents conduct the control and
follow-up experiments of para. 2 of ATTACHMENT A with respect to the Target. It
will also establish an SOP as provided under that paragraph. The Program for a
given Target will remain in effect for a period of [*] from the time of transfer
of reagents by CUSTOMER to NeoGenesis, with an option by CUSTOMER to renew the
Program for such Target for an additional [*] period on terms and conditions,
including level of support, that are mutually agreeable. CUSTOMER shall notify
NeoGenesis whether CUSTOMER wishes to extend the Program for a given Target for
an additional [*], no later than [*] prior to termination of the initial term.
NeoGenesis will apply its ALIS method to screen the NeoMorph Screening Library
for activity with respect to each Target for purposes of identifying potentially
useful chemical compounds for further

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       9
<Page>

evaluation and development. Alternatively, NeoGenesis shall apply ALIS screening
of libraries provided by CUSTOMER as described in ATTACHMENT A. Screening will
be performed pursuant to the screening protocol for the Program set forth in
ATTACHMENT A. NeoGenesis shall conduct the screening and deliver a Final Target
Report as described in ATTACHMENT A, but in any event within [*] following the
date that the applicable Target is delivered to NeoGenesis, unless the parties
agree in writing to extend the period for performance of the Program (the
SCREENING PERIOD).

2.3  GRANT OF RESEARCH LICENSE. CUSTOMER hereby grants NeoGenesis a
nonexclusive, nontransferable, royalty-free license to use CUSTOMER Know-How and
CUSTOMER Patent Rights solely for purposes of conducting the Program and
performing NeoGenesis's obligations to CUSTOMER under the Program. NeoGenesis
will not use CUSTOMER Know-How or CUSTOMER Patent Rights for any other purpose,
without CUSTOMER's prior written permission. NeoGenesis shall not (a) grant, or
attempt to grant, a sub-license to use CUSTOMER Know-How or CUSTOMER Patent
Rights to any Person without the express written consent of CUSTOMER, (b)
perform any tests on any of the Targets or using CUSTOMER assays or libraries
that are outside the scope of the Program, or (c) modify the Targets supplied by
CUSTOMER, including, without limitation, the making of any derivatives, analogs
or components thereof. In the event that NeoGenesis does not consume all of the
Targets, assays or libraries supplied by CUSTOMER in performance of the Program,
NeoGenesis will upon completion of the Program promptly, return to CUSTOMER any
quantities of such Target(s) and any derivatives, analogs or components thereof
as well as assays and CUSTOMER supplied Samples related thereto.

2.4  SCIENTIFIC REPORTS. (a) NeoGenesis will keep and maintain adequate records
containing laboratory data generated in the course of the Program to enable it
to furnish complete and accurate information to CUSTOMER regarding the Program
activities and results, including but not limited to all Preliminary Compounds,
Primary Active Compounds and NeoMorph Focused Libraries identified or used in
the Program and all NeoGenesis Program Intellectual Property developed during
the Program. All such written records of NeoGenesis shall be open to inspection
by CUSTOMER during normal business hours upon reasonable prior written notice.

     (b) NeoGenesis shall provide CUSTOMER with reasonably-detailed written
reports describing the results of the research performed pursuant to the Program
including but not limited to all Preliminary Compounds, Primary Active
Compounds, Selected Compounds and NeoMorph Focused Libraries identified or used
in the Program. Such reports shall be delivered to CUSTOMER at least monthly
during the Program. NeoGenesis will deliver a Primary Active Compounds Report
with respect to the Program work performed on each Target. NeoGenesis will also
deliver a Final Target Report on each Selected Compound after optimization and
screening of the NeoMorph Focused Libraries.

2.5 STEERING COMMITTEE. (a) A Steering Committee (STEERING COMMITTEE) shall be
responsible for day-to-day management of each Program. The Steering Committee
shall consist of four members, two members to be appointed by each of NeoGenesis
and CUSTOMER and such members may be appointed on a Target-by-Target basis. Each
party may with notice to the

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       10
<Page>

other substitute any of its members serving on the Steering Committee. The
initial CUSTOMER members shall be [*] and [*] and the initial NeoGenesis members
shall be ____________ and ____________. Each member of the Steering Committee
will have one vote and all decisions of the Steering Committee will be [*].

     (b) The Steering Committee shall be responsible for the management and
conduct of the Program and shall in particular: (i) consider, review and
amend the Program from time to time in such manner as may be appropriate;
(ii) monitor progress of the Program; (iii) report regularly to the
management of both parties upon the progress of the Program; (iv) be the
initial medium for transfer of information between the parties; and (v)
approve the allocation of FTEs for Program services beyond those specified in
paragraphs 1-7 and 9 of ATTACHMENT A (i.e., optimization of [*] Selected
Compounds to a Kd value of [*] and one round of optimization on [*] Selected
Compounds).

     (c) The Steering Committee shall hold meetings as mutually agreed by the
parties (but in no event less than three (3) times during the Screening Period)
to review the Program. The first meeting of the Steering Committee shall be held
within forty-five (45) days of each Target being designated and shall be held in
Cambridge, MA. Thereafter, meetings may be held by telephone or video conference
if requested by either party in writing to the other, PROVIDED THAT the parties
shall meet in person at least two (2) times during the Screening Period. Minutes
of all meetings setting forth decisions of the Steering Committee relative to
the Screening Program shall be prepared by the host party and circulated to both
parties within fifteen (15) days after each meeting, but minutes shall not
become official until approved by both parties (which approval the parties shall
use reasonable efforts to give within thirty (30) days of receipt of such
minutes).

     (d) The quorum for Steering Committee meetings shall be two, provided there
are at least one member from each of NeoGenesis and CUSTOMER present. The
Steering Committee will render decisions [*]. Disagreements among the Steering
Committee regarding the Program will be resolved via good-faith discussions;
PROVIDED, that in the event of a disagreement that cannot be resolved within
thirty (30) days after the date on which the disagreement arose, the matter
shall be referred to CUSTOMER's Vice President Research and NeoGenesis's Chief
Scientific Officer or their respective designees. Thereafter, if any such
disagreement is not resolved within sixty (60) days, then CUSTOMER shall have
the right to make the final decision.

2.6  DESIGNATED COMPOUNDS. (a) Within [*] following the delivery of the Primary
Active Compounds Report for a Target by NeoGenesis in accordance with Section
2.4 and ATTACHMENT A, CUSTOMER shall notify NeoGenesis whether it will classify
any Primary Active Compounds as a Selected Compound for further study or
optimization. If CUSTOMER does not identify any Selected Compound(s) within such
period, the license granted CUSTOMER under Section 3.1 shall terminate with
respect to the applicable Target and be of no further force or effect with
respect to such Target, and no further payment from CUSTOMER shall be due with
respect to such Target.

     (b) Within [*] following delivery of the Final Target Report for a Target
by NeoGenesis in accordance with Section 2.4 and ATTACHMENT A, CUSTOMER shall
notify NeoGenesis whether

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       11
<Page>

it will classify any of the Selected Compounds as a "DESIGNATED COMPOUND" for
further research and development in the CUSTOMER'S R&D Program; PROVIDED, that
CUSTOMER may not select more than [*] Designated Compounds in respect of each
Target. If CUSTOMER does not identify any Designated Compound(s) within such
period, the license granted CUSTOMER with respect to the applicable Target shall
terminate and be of no further force or effect with respect to the applicable
Target, and no further payment from CUSTOMER shall be due with respect to such
Target. Notwithstanding the foregoing, CUSTOMER may at any time during
CUSTOMER's R&D Program designate a compound from a CUSTOMER supplied library as
a Designated Compound and subject to the milestone payments payable pursuant to
Section 4.2(b) and royalty payments pursuant to Section 4.3(b), shall continue
to have the license granted CUSTOMER pursuant to Section 3.1.

     (c) Within [*] following receipt of notification from CUSTOMER identifying
Designated Compounds, NeoGenesis shall amend ATTACHMENT C to identify any
applicable NeoGenesis Patent Rights not previously identified to CUSTOMER.
Thereafter, NeoGenesis shall update ATTACHMENT C as necessary to identify any
applicable NeoGenesis Patent Rights not previously identified to CUSTOMER

2.7  PRODUCT DEVELOPMENT. CUSTOMER, at its sole expense, shall be solely
responsible for conducting the R&D Program related to Designated Compounds and
Licensed Products and shall do so using Commercially Reasonable Efforts.
CUSTOMER shall conduct the R&D Program in accordance with all Applicable Laws,
Good Laboratory Practices and Good Clinical Practices. It is understood that
CUSTOMER shall have no further obligation to develop, optimize or Commercialize
any Designated Compound or Licensed Product; PROVIDED, that CUSTOMER shall
notify NeoGenesis promptly following CUSTOMER's determination that it will
suspend or abandon efforts to conduct the R&D Program or to obtain Regulatory
Approvals or to Commercialize any Designated Compounds or Licensed Products.

2.8  MANUFACTURE OF PRODUCT. CUSTOMER shall be solely responsible, at its sole
expense, for and shall use its Commercially Reasonable Efforts to Manufacture
the Licensed Products in accordance with the Regulatory Approvals, Applicable
Laws, Good Laboratory Practices and Good Manufacturing Practices.

2.9  REGULATORY MATTERS. CUSTOMER, at its sole expense, shall use Commercially
Reasonable Efforts to prepare and file, in its own name, with the appropriate
Regulatory Authorities, all documents that are necessary to conduct clinical
studies of Licensed Products and Regulatory Approval applications that are
necessary to market and sell Licensed Products. CUSTOMER shall use Commercially
Reasonable Efforts to file Regulatory Approval applications in the Major
Countries, it being understood that CUSTOMER may determine that it is not
commercially reasonable to pursue Regulatory Approvals in particular countries
in cases where the difficulty and expense of obtaining Regulatory Approvals for
such countries cannot be justified in comparison to the profits that sales of
Licensed Products in such country are likely to yield. CUSTOMER shall notify
NeoGenesis when it makes such regulatory filings. CUSTOMER shall be solely
responsible for reporting all adverse events associated with any Licensed
Product to the appropriate Regulatory Authorities in accordance with Applicable
Laws.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       12
<Page>

2.10 MARKETING AND SALE. CUSTOMER, at its sole expense, shall be solely
responsible for the Commercialization of Licensed Products in the Territory and
shall use Commercially Reasonable Efforts to Commercialize each Licensed Product
in the Major Countries, it being understood that CUSTOMER may determine that it
is not commercially reasonable to pursue Commercialization in particular
countries in cases where the difficulty and expense of doing so cannot be
justified in comparison to the profits that sales of Licensed Products in such
country are likely to yield. CUSTOMER shall be solely responsible for
establishing the price of each Licensed Product sold by or on behalf of it
pursuant to this Agreement.

2.11 THIRD PARTY LICENSES. CUSTOMER shall be solely responsible for (a)
obtaining any and all licenses from third parties necessary or desirable to
perform its activities under the R&D Program and/or to Commercialize any
Licensed Product and (b) any and all consideration payable with respect to
such licenses. Notwithstanding the foregoing, in the event that CUSTOMER
obtains one or more licenses under patents owned by a third party necessary
or desirable to Commercialize any Licensed Product, based on CUSTOMER's good
faith determination, CUSTOMER may, beginning from the date of such third
party license, deduct [*] of the amount paid to such third party under such
licenses from the royalty obligations due to NeoGenesis under Section 4.3,
provided that (i) such third party patent primarily relates to the Designated
Compound and (ii) such deductions shall not exceed [*] of such royalties with
respect to such Licensed Product.

2.12 COMPLIANCE WITH LAW. CUSTOMER shall conduct the R&D Program and conduct its
Manufacturing operations in a safe and prudent manner, in compliance with all
Applicable Laws (including, but not limited to, occupational safety and health,
public safety and health, protecting the environment, the disposal of wastes,
Good Clinical Practices, Good Laboratory Practices and Good Manufacturing
Practices), and in compliance with all applicable provisions of this Agreement.
CUSTOMER shall obtain all necessary registrations and permits pertaining to
CUSTOMER'S activities contemplated by this Agreement. NeoGenesis shall conduct
all of its activities under this Agreement in a safe and prudent manner, in
compliance with all Applicable Laws, and in compliance with all applicable
provisions of this Agreement. NeoGenesis shall obtain all necessary
registrations and permits pertaining to NeoGenesis' activities contemplated by
this Agreement.

2.13 PERIODIC REVIEW. CUSTOMER and NeoGenesis shall periodically meet, at such
times and places as are mutually agreed upon, for CUSTOMER to provide NeoGenesis
with an update on the status of the progress of CUSTOMER's Commercialization of
each Licensed Product, PROVIDED, HOWEVER, that such meetings shall occur no more
than once per calendar year unless the parties agree, in writing, to meet more
or less often. CUSTOMER and NeoGenesis shall each be responsible for its own
expenses incurred in connection with attending such meetings.

3.   LICENSE; PROPRIETARY RIGHTS

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       13
<Page>

3.1  GRANT OF LICENSE. (a) Subject to the terms and conditions of this
Agreement, including the payment of all applicable fees, NeoGenesis hereby
grants to CUSTOMER, and CUSTOMER hereby accepts, an exclusive, worldwide, right
and license, within the Territory and within the Field, to use the NeoGenesis
Know-How and NeoGenesis Patent Rights and NeoGenesis's undivided interest in any
Program Intellectual Property and Program Patent Rights that are jointly owned
by NeoGenesis and CUSTOMER, as embodied in or related to Designated Compound(s)
(collectively, the LICENSED TECHNOLOGY), to (i) identify, research, develop,
make, have made and use such Designated Compound to develop Licensed Products
and (ii) to develop, make, have made, use, distribute for sale, promote, market,
offer for sale, sell, have sold, import and export Licensed Products; PROVIDED,
that the exclusivity of such license shall be subject in the case of "Generic
Patent Rights" to the retained rights described in Section 3.2(c)(iv). CUSTOMER
may grant sublicenses of its rights under this Section 3.1; PROVIDED that
CUSTOMER: (1) obtains each sublicensee's written agreement to be subject to the
same obligations as is CUSTOMER under Sections 2.13, 3.1(c), 3.2, 4.4-4.7, 5.2,
7.1(b), 7.2(b), 7.4, 8.1, 8.3 and 8.4 of this Agreement (or substantially
identical provisions) and (2) shall remain responsible for the performance of
all of its obligations under this Agreement, whether such obligations are
performed by CUSTOMER, its Affiliates or any of its sublicensees.

     (b) The license granted under this Section 3.1 shall be treated as a
license of rights to "intellectual property" (as defined in Section 101(56) of
Title 11 of the United States Code, as amended (the BANKRUPTCY CODE)) for
purposes of Section 365(n) of the Bankruptcy Code. The parties agree that
CUSTOMER may elect to retain and may fully exercise all of its rights and
elections under the Bankruptcy Code PROVIDED, that it abides by the terms of
this Agreement.

     (c) CUSTOMER shall mark or have marked all containers or packages of
Licensed Products that are the subject of the license granted under this Section
3.1 in accordance with the patent marking laws of the jurisdiction in which such
Licensed Products are manufactured, used or sold.

3.2  RETAINED RIGHTS. (a) This Agreement does not convey to CUSTOMER any
ownership rights in any NeoGenesis Know-How or NeoGenesis Patent Rights by
implication, estoppel or otherwise except for the rights expressly granted in
Section 3.1. Title to the NeoGenesis Know-How and NeoGenesis Patent Rights shall
at all times remain vested in NeoGenesis. This Agreement does not convey to
NeoGenesis any ownership rights in any CUSTOMER Know-How or CUSTOMER Patent
Rights by implication, estoppel or otherwise except for the rights expressly
granted in Section 2.3. Title to the CUSTOMER Know-How and CUSTOMER Patent
Rights shall at all times remain vested in CUSTOMER. Title to and any interest
in Program Intellectual Property described in clause (a) of the Program
Intellectual Property definition shall be the property of NeoGenesis and is
included in the definition of NeoGenesis Know-How or NeoGenesis Patent Rights,
as the case may be, subject to the licenses granted to CUSTOMER under Section
3.1. Title to and any interest in Program Intellectual Property described in
clause (b) of the Program Intellectual Property definition shall be jointly held
by CUSTOMER and NeoGenesis, subject to the licenses granted to CUSTOMER under
Section 3.1. Title to and any interest in Program Intellectual Property
described in clause (c) of the Program Intellectual Property definition shall be
the property of CUSTOMER and is included in the definition of CUSTOMER Know-How
or CUSTOMER Patent Rights, as the case may be.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       14
<Page>

     (b) Patent counsel mutually acceptable to the parties and selected by the
Steering Committee in accordance with Section 3.3(c) shall determine
inventorship of all intellectual property that arises from the transactions
contemplated by this Agreement in accordance with U.S. patent law (and other
U.S. intellectual property law) when determining whether such intellectual
property is (i) CUSTOMER Know-How or CUSTOMER Patent Rights or (ii) NeoGenesis
Know-How or NeoGenesis Patent Rights or (iii) if such intellectual property is
Program Intellectual Property, whether Program Intellectual Property is jointly
owned or is owned solely by NeoGenesis or by CUSTOMER.

     (c) Except as otherwise provided in Section 3.2(c)-(d), NeoGenesis shall
retain the following rights with respect to the following NeoGenesis Know-How
and NeoGenesis Patent Rights and Program Intellectual Property:

         (i)      NeoGenesis shall continue to use its NeoMorph Screening
                  Library to screen target proteins for other parties; PROVIDED,
                  that (i) NeoGenesis shall mask the Primary Active Compounds
                  from the NeoMorph Screening Library during the Program and
                  during any period when CUSTOMER is pursuing an R&D Program or
                  Commercialization of a Designated Compound selected from such
                  Primary Active Compounds. In addition, NeoGenesis shall mask
                  any Selected Compounds, and Designated Compound(s) from the
                  NeoMorph Screening Library for as long as CUSTOMER is pursuing
                  an R&D Program or Commercialization of a Designated Compound
                  or a Licensed Product.

         (ii)     NeoGenesis shall retain all rights under its intellectual
                  property to continue to use Compounds created as part of the
                  Program but not selected as Selected Compounds or Designated
                  Compounds.

         (iii)    NeoGenesis shall retain all rights in and continue to use
                  compound libraries that are designed by it as part of the
                  Program using QSCD or other structural information.

         (iv)     NeoGenesis shall retain, with respect to Generic Patent
                  Rights, the exclusive right to practice such Generic Patent
                  Rights and to license third parties to practice those Generic
                  Patent Rights as necessary to research, develop, make, have
                  made, use, distribute for sale, import and sell any product;
                  PROVIDED, that such product shall not have the "same active
                  ingredient" as a Licensed Product, it being expressly
                  understood and agreed that CUSTOMER holds exclusive rights
                  with respect to the practice of the Generic Patent Rights as
                  necessary to research, develop, make, have made, use,
                  distribute for sale, import and sell any Licensed Product or
                  any product having the same active ingredient as any Licensed
                  Product.

     (d) NeoGenesis will not use the NeoGenesis Know-How, NeoGenesis Patent
Rights, Program Know-How or Program Patent Rights with respect to any Target
selected by CUSTOMER for a period of [*] following delivery of such Target to
NeoGenesis by

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       15
<Page>

CUSTOMER. It is understood and acknowledged by NeoGenesis that the
restrictions imposed by this Section 3.2 will operate independently of any
patent rights that CUSTOMER may hold or be granted under this Agreement with
respect to any Target.

3.3  DISCLOSURE; PATENT PROSECUTION. (a) Each of NeoGenesis and CUSTOMER shall
promptly disclose to the other knowledge of any Program Intellectual Property,
described under clause (a) or (b) of the definition of Program Intellectual
Property and will be subject to the provisions of this Agreement. Within
forty-five (45) days following the date of such disclosure regarding the
existence of particular Program Intellectual Property that is jointly owned, the
parties shall confer as to appropriate protection for such Program Intellectual
Property. Except as otherwise expressly provided herein, all other inventions
and discoveries governed by this Agreement shall be owned based on inventorship,
as inventorship is determined in accordance with United States patent law.
Except as specifically provided under this Agreement, the transfer of physical
possession and use of any technology by CUSTOMER or NeoGenesis, as the case may
be, shall not be (nor be construed as) a license, sale, lease, offer to sell or
lease, or other transfer of title of such technology to CUSTOMER or NeoGenesis,
as the case may be.

     (b) Except as provided in this Section 3.3 or Section 3.4, NeoGenesis shall
have the sole right, at its cost, but not the obligation, to file, prosecute,
and maintain each of the NeoGenesis Patent Rights throughout the Territory.
NeoGenesis shall keep CUSTOMER currently advised as to the status of all patents
and patent applications with respect to the NeoGenesis Patent Rights and shall
supply CUSTOMER promptly with copies of all patents, patent applications,
substantive patent office actions, substantive responses received or filed in
connection with such applications. CUSTOMER may itself or through its attorney
offer comments and suggestions with respect to the matters that are the subject
of this Section 3.3(b) and NeoGenesis agrees to consider in good faith such
comments and suggestions; PROVIDED that nothing herein shall obligate NeoGenesis
to adopt or follow such comments or suggestions. In the event that NeoGenesis
elects not to file for patent protection under the NeoGenesis Patent Rights or
elects not to prosecute or maintain a patent or patent application under the
NeoGenesis Patent Rights it shall notify CUSTOMER of such decision at least
forty-five (45) days prior to the due date of any action or payment due.
CUSTOMER shall have the right, but not the obligation to assume the
responsibility therefor then at its own cost and expense. It is understood that
while NeoGenesis has not sought, and will not seek, patent protection on any of
the compounds that will be screened in the conduct of the Screening Program,
NeoGenesis may seek patent protection for Selected Compounds, including analogs,
homologs and isomers thereof, in the event and to the extent that NeoGenesis
determines it can seek "generic composition of matter claims" (which for
purposes of this Agreement shall not include any Target specific claims of
utility) with respect to such compounds (any such patents are referred to as
"GENERIC PATENT RIGHTS"). Upon the selection by CUSTOMER of a Designated
Compound, CUSTOMER shall have the sole right, at its cost, but not the
obligation, to file, prosecute, and maintain each of the NeoGenesis Patent
Rights related to the Licensed Technology embodied in or related to such
Designated Compound. In the event that CUSTOMER elects not to file for patent
protection under such Licensed Technology or elects not to prosecute or maintain
a patent or patent application thereunder it shall notify NeoGenesis of such
decision at least forty-five (45) days

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       16
<Page>

prior to the due date of any action or payment due. NeoGenesis shall have the
right, but not the obligation to assume the responsibility therefor then at its
own cost and expense.

     (c) CUSTOMER and NeoGenesis, acting through the Steering Committee, shall
select and retain patent counsel mutually acceptable to each of them for the
purpose of preparing, prosecuting, issuing and maintaining appropriate patent
applications concerning jointly owned Program Intellectual Property on behalf of
both CUSTOMER and NeoGenesis. Any differences between NeoGenesis and CUSTOMER
with respect to preparation, filing, prosecution, issuance and maintenance
matters will be discussed and resolved to their mutual satisfaction using the
procedures specified in Section 9.1, if necessary. The parties shall share
equally in all expenses associated with the preparation, filing, prosecution,
issuance and maintenance of patents or other intellectual property protection
for jointly owned Program Intellectual Property; PROVIDED, that in the event
that the parties disagree regarding the costs of a particular action and either
party elects not to pursue a particular action (e.g., patent coverage in a
particular country) either party shall have the right to assume such costs and
to have such action taken; PROVIDED FURTHER that the rights of the party which
elects not to participate in such expenses shall not include any such Program
Patent Rights that are the subject of such action (e.g., patent coverage in a
particular country) unless such party reimburses the other party for one half
(50%) of the costs of such action PLUS interest on such reimbursement from the
date such costs were incurred calculated at the rate specified in Section
4.4(b).

     (d) CUSTOMER shall have the sole right, but not the obligation, to file,
prosecute, and maintain, at CUSTOMER's sole expense, each of the CUSTOMER Patent
Rights throughout the Territory and shall be responsible for all the costs
related thereto.

3.4  ENFORCEMENT. (a) NeoGenesis shall be solely responsible for defense and
enforcement of NeoGenesis Know-How and NeoGenesis Patent Rights but excluding
Licensed Technology within the Field and the Territory. In the event that legal
proceedings with respect to such Licensed Technology also materially affect
intellectual property rights of NeoGenesis that relate to other then active
NeoGenesis research, development or commercialization programs outside the
Field, the parties agree to cooperate in good faith with respect to such defense
or action. CUSTOMER shall be solely responsible for the defense and enforcement
of CUSTOMER Know-How and CUSTOMER Patent Rights.

     (b) Except as otherwise provided in Section 3.4(a), CUSTOMER shall have the
first option to pursue any enforcement or defense of Licensed Technology within
the Field and the Territory; PROVIDED, that CUSTOMER pays all costs and expenses
related to the same, keeps NeoGenesis reasonably informed of its progress and
provides NeoGenesis with copies of any documents related to such proceedings as
permitted under any relevant protective order and reasonable notice of all
proceedings relating to same. CUSTOMER's costs in prosecuting such matters shall
be subject to reimbursement in accordance with Section 3.4(d). CUSTOMER shall
notify NeoGenesis of its decision to exercise its right to enforce Licensed
Technology as soon as possible, but not later than sixty (60) days following its
discovery or receipt of notice of the alleged infringement.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       17
<Page>

     (c) Unless CUSTOMER and NeoGenesis have otherwise agreed not to pursue such
infringement for business reasons, if CUSTOMER does not exercise its option to
enforce or defend any Licensed Technology or and within (90) days of exercising
its option, CUSTOMER (i) has not persuaded the alleged infringer to desist, (ii)
is not diligently pursuing an infringement action or diligently defending the
validity or enforceability of Licensed Technology at issue, as determined by
NeoGenesis in its reasonable discretion, or (iii) has not provided NeoGenesis
with evidence of bona fide negotiations of a sublicense agreement with the
alleged infringer, then NeoGenesis shall have the right to pursue the alleged
infringer or take control of any action initiated by CUSTOMER at NeoGenesis's
own expense. In any such case, CUSTOMER will substitute NeoGenesis as party
plaintiff for purposes of pursuing any alleged infringer.

     (d) Any recoveries by settlement or otherwise, with regard to Licensed
Technology in any suit handled by one party pursuant to Section 3.4(b) or
Section 3.4(c) shall be applied first in satisfaction of any unreimbursed
expenses and legal fees of the litigant relating to the suit or settlement
thereof and of the other party in providing requested cooperation. Any remaining
recoveries shall (i) to the extent that the infringement is based on the
development, manufacture, commercialization or use of Licensed Products in the
Field, be deemed Net Sales and NeoGenesis shall receive an amount equal to the
royalty due on such Net Sales and CUSTOMER shall receive the balance of such
remainder; or (ii) to the extent that the infringement is not based on the
development, manufacture, commercialization or use of Licensed Products in the
Field, such remainder shall be paid: (1) [*] to NeoGenesis if NeoGenesis is the
prosecuting party, (2) [*] to NeoGenesis and [*] to CUSTOMER if CUSTOMER is the
prosecuting party, or (3) if the parties jointly participate, other than the
assistance that each party is required to provide to the litigating party
pursuant to Section 3.4(b) or Section 3.4(c), as the case may be, and for which
it has been reimbursed in prosecuting legal proceedings relating to infringement
or defense of the Licensed Technology, any damages and costs received in any
proceedings or by way of settlement shall be split fifty percent (50%) to
NeoGenesis and fifty percent (50%) to CUSTOMER. No settlement, or consent
judgment or other voluntary final disposition of any suit regarding Licensed
Technology may be entered into without the consent of the other party, which
consent shall not be unreasonably withheld.

     (e) In any infringement suit as either party may institute to enforce
Licensed Technology, or in any declaratory judgment action alleging invalidity
or non-infringement of any Licensed Technology brought against NeoGenesis or
CUSTOMER, the other party shall, at the request and expense of the party
initiating or defending the suit or action, cooperate and assist in all
reasonable respects, having its employees testify when requested and making
available relevant records, papers, information, specimens and the like.

     (f) Notwithstanding the provisions of Section 3.4(b), if a declaratory
judgment action or other action alleging invalidity or non-infringement of any
of the patents within Licensed Technology is brought, NeoGenesis at its initial
option, shall have the right, within sixty (60) days after notification of same,
to assume defense of the action at its expense, but CUSTOMER shall be entitled
to participate in such action, at its own expense.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       18
<Page>

4.   PRICING; PAYMENT

4.1  SCREENING FEE. CUSTOMER will pay NeoGenesis a screening fee of [*] per
accepted Target for the NeoGenesis services pursuant to the Program with respect
to such Target. CUSTOMER will pay this fee within [*] of the effective date of a
designated Target being accepted by NeoGenesis. In addition, CUSTOMER will pay
NeoGenesis a fee of [*] per Target in FTE funding for the Program ([*] people
for [*] at an FTE of [*]). Such FTE funding shall be paid at the commencement of
each Program. Any additional FTE funding for a Target (for Program services
beyond those specified in paragraphs 1-7 and 9 of ATTACHMENT A (i.e.,
optimization of three Selected Compounds to a Kd value of [*] and [*] of
optimization on [*] Selected Compounds) must be approved by the Steering
Committee on a Target-by-Target basis and will be charged at the rate of [*] per
FTE. In addition to the fees described above, at the completion of each Program
CUSTOMER shall pay to NeoGenesis a fee of [*].

4.2  MILESTONES. (a) CUSTOMER will pay NeoGenesis milestone payments in respect
of Licensed Products that are related to Designated Compounds selected from
NeoGenesis supplied libraries as specified in this Section 4.2(a).

         (i)  Within thirty (30) days following the date on which CUSTOMER first
              identifies a Designated Compound as having acceptable "cellular
              efficacy" against the relevant Target, as documented in secondary
              cell-based bioassays performed by or on behalf of CUSTOMER,
              CUSTOMER will pay NeoGenesis [*]. CUSTOMER shall promptly notify
              NeoGenesis of the results of such secondary bioassays. The
              Steering Committee shall define the acceptable cellular efficacy
              for each Target at the first Steering Committee meeting following
              the designation of such Target (which shall occur within 30 days
              of the designation of such Target) and it is understood and agreed
              that notwithstanding the provisions of Section 2.2, NeoGenesis
              shall not be required to accept a Target until the Steering
              Committee defines acceptable cellular efficacy. Cellular efficacy
              shall be based on the functional activity in a cellular assay as
              well as acceptable cytotoxicity and shall take into consideration
              the novelty and or patentability of compounds that have achieved
              cellular efficacy, or compositions containing or methods of using
              those compounds.

         (ii) Within thirty (30) days following the date on which CUSTOMER files
              its first IND with the FDA on any Licensed Product or makes a
              comparable filing with regulatory authorities in another Major
              Country (including both a centralized filing, including a Major
              Country, or a filing in any Major Country), CUSTOMER will pay
              NeoGenesis [*].

         (iii)Within thirty (30) days following the date on which the first
              administration or dosing of any Licensed Product occurs in the
              first Phase II Clinical Trials relating to any Licensed Product,
              CUSTOMER will pay NeoGenesis [*]. PHASE II CLINICAL TRIALS means
              any safety and/or efficacy clinical studies of any Licensed
              Product in human patients to determine initial efficacy and dose
              range finding before embarking on Phase III clinical studies.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       19
<Page>

         (iv) Within thirty (30) days following the date on which CUSTOMER first
              submits an NDA covering any Licensed Product with the FDA, or
              alternatively makes a comparable filing with regulatory
              authorities in another Major Country, (including both a
              centralized filing, including a Major Country, or a filing in a
              Major Country) CUSTOMER will pay NeoGenesis [*].

         (v)  Within thirty (30) days following the date on which CUSTOMER first
              receives approval from the FDA permitting the manufacture and sale
              of a Licensed Product or alternatively a comparable Regulatory
              Approval for another Major Country, CUSTOMER will pay NeoGenesis
              [*].

         (b) In the event that CUSTOMER, pursuant to Section 2.6, designates a
compound from a CUSTOMER supplied library as a Designated Compound, CUSTOMER
will pay NeoGenesis milestone payments in respect of Licensed Products relating
to such Designated Compound as specified in this Section 4.2(b).

         (i)  Within thirty (30) days following the date on which CUSTOMER
              identifies the first Designated Compound as having acceptable
              cellular efficacy against the relevant Target, as documented in
              secondary cell-based bioassays performed by or on behalf of
              CUSTOMER, CUSTOMER will pay NeoGenesis [*]. CUSTOMER shall
              promptly notify NeoGenesis of the results of such secondary
              bioassays.

         (ii) Within thirty (30) days following the date on which CUSTOMER files
              its first IND with the FDA on any Licensed Product or makes a
              comparable filing with regulatory authorities in another Major
              Country (including both a centralized filing, including a Major
              Country, or a filing in any Major Country), CUSTOMER will pay
              NeoGenesis [*].

         (iii)Within thirty (30) days following the date on which the first
              administration or dosing of any Licensed Product occurs in the
              first Phase II Clinical Trials relating to any Licensed Product,
              CUSTOMER will pay NeoGenesis [*].

         (iv) Within thirty (30) days following the date on which CUSTOMER first
              submits an NDA covering any Licensed Product with the FDA, or
              alternatively makes a comparable filing with regulatory
              authorities in another Major Country, (including both a
              centralized filing, including a Major Country, or a filing in a
              Major Country) CUSTOMER will pay NeoGenesis [*].

         (v)  Within thirty (30) days following the date on which CUSTOMER first
              receives approval from the FDA permitting the manufacture and sale
              of a Licensed Product or alternatively a comparable Regulatory
              Approval for another Major Country, CUSTOMER will pay NeoGenesis
              [*].

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       20
<Page>

     (c) Notwithstanding the foregoing, the parties understand and agree that
none of the payments listed in Section 4.2(a)(i)-(v) or Section 4.2(b)(i)-(v)
will be due before [*]. Milestones identified in Section 4.2(a)(i)-(v) and
Section 4.2(b)(i)-(v) shall be due only for the first Licensed Product in
respect of each Target, regardless of the number of Licensed Products developed
and/or commercialized by CUSTOMER for such Target; PROVIDED that in the event
that any milestones under Section 4.2(b)(i)-(v) are first paid for a Licensed
Product with respect to a Target and subsequently, CUSTOMER achieves a
corresponding milestone under Section 4.2(a)(i)-(v) for another Licensed Product
with respect to the same Target, then CUSTOMER shall only be required to pay the
difference between the Section 4.2(b)(i)-(v) milestone payment already paid and
the Section 4.2(a)(i)-(v) milestone payment subsequently achieved. On the date
any one milestone with respect to a Licensed Product is achieved, all lower
numbered unachieved milestones shall be deemed to have been achieved with
respect to that Licensed Product.

4.3  ROYALTIES. Not later than forty-five (45) days following each March 31,
June 30, September 30 and December 31 commencing with the First Commercial Sale
of Licensed Products in any country, CUSTOMER shall pay to NeoGenesis royalties
by country for the most recent three-month period then ended, equal to (a) [*]
of Net Sales in such period for Licensed Products related to Designated
Compounds selected from NeoGenesis supplied libraries, and (b) [*] for Licensed
Products related to Designated Compounds selected from CUSTOMER supplied
libraries. CUSTOMER shall pay royalties with respect to each Licensed Product on
a country by country basis (i) until the expiration or revocation or complete
rejection (without the right of appeal) of the last to expire or to be revoked
or to be completely rejected of any NeoGenesis Patent Rights covering such
Licensed Product in the country in which the Licensed Product is manufactured or
sold, or (ii) if no NeoGenesis Patent Rights exist in the relevant country
covering the manufacture, use or sale of the relevant Licensed Product, until
[*] from the First Commercial Sale of such Licensed Product in such country.
Notwithstanding the foregoing or anything in this Agreement to the contrary, no
royalties shall be due with respect to Licensed Products which include
Designated Products which are identified using CUSTOMER supplied libraries,
unless the development, manufacture, use, or sale of which, absent the license
granted under this Agreement, would infringe a Valid Claim of s patent within
NeoGenesis Patent Rights.

4.4  REMITTANCE. (a) All royalties and milestone payments required under this
Section 4 shall be payable in full in the United States in United States
Dollars, regardless of the countries in which sales are made. For the purpose of
computing Net Sales for which a currency other than United States Dollars is
received, such currency shall be converted into United States Dollars at the
average exchange rate for buying United States Dollars set forth in THE WALL
STREET JOURNAL for the calendar quarter in which such sales were made.

     (b) In the event that any payment due NeoGenesis under this Agreement is
not made when due, the amount due shall accrue interest beginning on the fifth
day following the final date on which such payment was due, calculated at the
annual rate equal to two percent (2%) above the prime interest rate reported in
the WALL STREET JOURNAL for the due date, calculated from the due date until
paid in full. Such payment when made shall be accompanied by all interest so
accrued.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       21
<Page>

Said interest and the payment and acceptance thereof shall not negate or waive
the right of NeoGenesis to any other remedy, legal or equitable, to which it may
be entitled because of the delinquency of the payment.

     (c) If at any time legal restrictions within any country in the Territory
prevent the conversion of the local currency and such currency cannot be removed
from such country such that prompt remittance by CUSTOMER of any royalties owed
by CUSTOMER to NeoGenesis in respect of sales in such country is prevented,
CUSTOMER shall use its best efforts to make payment through any lawful means or
methods that may be available as CUSTOMER shall reasonably determine and, if
royalties in any country cannot be remitted to NeoGenesis for any reason within
three (3) month after the end of the relevant reporting period, then CUSTOMER
shall pay NeoGenesis in the local currency of such country by deposit of the
relevant royalties in a bank account in such country designated by NeoGenesis.

4.5  RECORDS. CUSTOMER, its Affiliates and sublicensees shall keep and maintain
for a period of at least three (3) years from the date of each payment of
royalties, records (prepared in accordance with United States Generally Accepted
Accounting Principles, consistently applied) sufficient to determine the amounts
of Net Sales and payments due under Section 4.3. Within forty-five (45) days
following each March 31, June 30, September 30 and December 31 in which payments
are due under Section 4.3, CUSTOMER shall provide NeoGenesis with a report
including at least: (a) the quantities of Licensed Products and Combination
Products that CUSTOMER, its Affiliate(s) and sublicensee(s) sold during the
preceding quarter in each country in which Licensed Products or Combination
Products were sold; (b) the monetary amount, in the national currency of such
country, of such sales; (c) actual Net Sales, by country; (d) the currency
conversion rate used and U.S. dollar-equivalent of such sales; (e) the
calculation of royalties thereon; and (f) the total royalties so computed and
due NeoGenesis. Such reports shall be submitted to NeoGenesis whether or not any
sales of Licensed Product have been made during such period. Upon delivery of
the report due for the period ending December 31 of each year, CUSTOMER shall
also report to NeoGenesis the aggregate royalties due NeoGenesis for the entire
preceding year.

4.6  INSPECTION. CUSTOMER and its Affiliates and sublicensees shall each make
its records available for inspection by an independent certified public
accountant during regular business hours at such place or places where such
records are customarily kept, upon reasonable notice from NeoGenesis, solely to
verify the accuracy of the reports and payments. Such inspection right shall not
be exercised more than once in any calendar year nor more than once with respect
to sales of Licensed Products in any given payment period. NeoGenesis agrees to
hold in strict confidence all information concerning royalty payments and
reports, and all information learned in the course of any audit or inspection,
except to the extent necessary for NeoGenesis to reveal such information in
order to enforce its rights under this Agreement or, subject to compliance with
the provisions of Section 5, if disclosure is required by law, regulation or
judicial order. Any person or entity conducting such audit or inspection will
agree in writing with NeoGenesis to treat all records reviewed in the course of
the audit or inspection as the Confidential Information of CUSTOMER under terms
and conditions no less restrictive than the terms contained in Section 5.2. The
CUSTOMER may require the independent certified accountant to

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       22
<Page>

sign a standard non-disclosure agreement before providing the independent
certified accountant access to the CUSTOMER'S facilities or records. The results
of each inspection, if any, shall be binding on both parties. NeoGenesis shall
pay for such inspections, except that in the event there is any upward
adjustment in aggregate royalties payable for any year shown by such inspection
of more than five percent (5%) of the amount paid, in which case CUSTOMER shall
pay for such inspection.

4.7  TAXES. Except for income taxes that may be assessed against NeoGenesis, all
taxes and charges that may be imposed by any government taxing authority on the
amounts paid by CUSTOMER to NeoGenesis under this Agreement shall, to the extent
permitted under applicable law, be paid by CUSTOMER for NeoGenesis's account. In
the event CUSTOMER is required to pay the taxes or charges for the account of
NeoGenesis, and therefore withholds such taxes or charges from the amounts paid
to NeoGenesis under this Agreement, CUSTOMER shall deliver to NeoGenesis true
copies of the receipts and/or returns covering all such payments and the
appropriate documentation which is necessary to obtain a tax credit, to the
extent such tax credit can be obtained. Each party shall provide assistance to
the other party in seeking any benefits available to such party with respect to
government tax withholdings by any relevant law or double tax treaty.

4.8  CONVERTIBLE DEBT. In connection with the transactions contemplated in this
Agreement, on the Effective Date, NeoGenesis will borrow $2,000,000 from
CUSTOMER on the terms and conditions contained in the Convertible Note Purchase
Agreement to be entered into by the parties on the Effective Date and a
Convertible Note to be issued by NeoGenesis to CUSTOMER on the Effective Date.

4.9  DILIGENCE FEE. In the event that within [*] of the Effective Date both: (i)
NeoGenesis has not completed an initial public offering (IPO) AND (ii) CUSTOMER
has not filed an IND with the FDA on any Licensed Product as described in
Section 4.2(a)(ii) or 4.2(b)(ii), then CUSTOMER shall pay NeoGenesis [*]. In the
event that either (i) or (ii) above has occurred then no such fee shall be due

5.   CONFIDENTIALITY

5.1  PUBLICITY. Except as is necessary to comply with applicable laws and
regulations or to enforce their respective rights under this Agreement, and
except as otherwise agreed to by the parties in writing, the parties shall: (a)
keep the material terms of this Agreement and results of any Program
confidential; (b) agree upon the text and the exact timing of an initial public
announcement relating to the transactions contemplated by this Agreement as soon
as practicable after the Effective Date (such agreement not to be unreasonably
withheld or delayed); and (c) agree on the text and the timing of any other
public announcements regarding this Agreement or the transactions contemplated
herein that provide additional information. The parties are free to use the
information in agreed announcements in subsequent references to this Agreement.
Notwithstanding the foregoing, following the selection of a Designated Compound
by CUSTOMER as described in Section 2.6, CUSTOMER shall be free to disclose
NeoGenesis

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       23
<Page>

Know-How related to the Designated Compound and Program results to the extent
necessary and appropriate in connection with CUSTOMER's efforts to obtain
Regulatory Approvals for Licensed Products.

5.2  CONFIDENTIALITY. (a) Confidential Information of each party will be used by
the other party solely for the purposes permitted by this Agreement. All
Confidential Information will be received and held in confidence by the
receiving party, subject to the provisions of this Agreement. Each party
acknowledges that it will not obtain any rights of any sort in or to the
Confidential Information of the other party as a result of such disclosure and
that any such rights must be the subject of a separate written agreement(s)
except as contemplated by the last sentence of Section 5.1. Either party may
only disclose the general nature, but not the specific financial terms, of this
Agreement without the prior consent of the other party; PROVIDED that either
party may provide a copy of this Agreement or disclose the terms of this
Agreement (i) to any finance provider in conjunction with a financing
transaction, if such finance provider agrees to keep this Agreement
confidential, (ii) to any legal or financial advisor of such party, or (iii) in
response to a subpoena or other validly issued administrative or judicial
process requesting disclosure of same; PROVIDED, the party that receives such
order or process provides prompt notice to the disclosing party before making
any disclosure and permits the disclosing party to oppose or narrow such request
for disclosure and supports any of disclosing party's reasonable efforts to
oppose such request (at disclosing party's expense) and shall disclose the terms
of this Agreement only in the event of a final judgment or administrative order
requiring such disclosure, and only to the extent necessary to comply with such
request.

     (b) Each party will restrict disclosure of the other party's Confidential
Information to those of its employees to whom it is necessary to disclose such
Confidential Information in connection with the purposes permitted under Section
5.2(a). Each party shall use reasonable efforts, including at least efforts
fully commensurate with those employed by the party for the protection of its
own Confidential Information, to protect the Confidential Information of the
other party.

     (c) Nothing herein shall prevent a receiving party from disclosing all or
part of the Confidential Information as necessary pursuant to the lawful
requirement of a governmental agency or when disclosure is required by operation
of law; PROVIDED that prior to any such disclosure, the receiving party shall
use reasonable efforts to: (i) promptly notify the disclosing party in writing
of such requirement to disclose; and (ii) cooperate fully with the disclosing
party in protecting against any such disclosure or obtaining a protective order.

6.   REPRESENTATIONS AND WARRANTIES.

6.1  AUTHORIZATION; ENFORCEABILITY; INFRINGEMENT. Each of CUSTOMER and
NeoGenesis represent and warrant to the other that: (a) it is a corporation or
limited liability company, as applicable, duly organized and validly existing
under the laws of its jurisdiction of organization and has all requisite power
and authority to enter into this Agreement; (b) it is duly authorized by all
requisite action to execute, deliver and perform this Agreement and to
consummate the transactions contemplated hereby, and that the same do not
conflict or cause a default with

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       24
<Page>

respect to such party's obligations under any other agreement; (c) it has duly
executed and delivered this Agreement; and (d) it is authorized to disclose any
and all Confidential Information made available to the other party pursuant to
this Agreement. In addition, NeoGenesis represents and warrants that it is not
aware of any patent held by any third party which would prevent NeoGenesis' or
CUSTOMER's use of the NeoGenesis Patent Rights or NeoGenesis Know-How in
performance of the Program.

6.2  NEOGENESIS PERFORMANCE. NeoGenesis hereby represents and warrants to
CUSTOMER that: (a) NeoGenesis shall perform the Program using qualified
personnel and in a good and workmanlike manner consistent with industry
standards of companies that are comparable to NeoGenesis performing similar
activities under similar circumstances; (b) as of the Effective Date, there is
no agreement known to NeoGenesis to which it is a party and by which it is bound
that would conflict with or be breached by NeoGenesis granting CUSTOMER the
license in Section 3.1 or NeoGenesis' performance under this Agreement; and (c)
NeoGenesis is unaware of any patent and other rights owned or controlled by any
third Person which would be infringed by the NeoGenesis Patent Rights or the
NeoGenesis Know-How or the performance of its obligations under this Agreement.

6.3  DISCLAIMER. (A) EXCEPT FOR THE WARRANTIES EXPRESSLY MADE IN SECTIONS
6.1-6.2, NEITHER PARTY MAKES ANY OTHER REPRESENTATION OR WARRANTY, EITHER
EXPRESS OR IMPLIED (WHETHER WRITTEN OR ORAL), INCLUDING, WITHOUT LIMITATION ANY
WARRANTY AGAINST INFRINGEMENT OF ANY THIRD PARTY PATENT OR OTHER INTELLECTUAL
PROPERTY RIGHTS, ANY WARRANTY OF MERCHANTABILITY OR ANY WARRANTY OF FITNESS FOR
A PARTICULAR PURPOSE WITH RESPECT TO THE NEOMORPH SCREENING LIBRARY, THE
NEOMORPH FOCUSED LIBRARIES, QSCD, THE PRELIMINARY COMPOUNDS, THE PRIMARY ACTIVE
COMPOUNDS, THE SELECTED COMPOUNDS, THE DESIGNATED COMPOUNDS, THE TARGETS, THE
LICENSED PRODUCTS, THE NEOGENESIS KNOW-HOW, THE CUSTOMER KNOW-HOW, THE SCOPE,
VALIDITY OR ENFORCEABILITY OF THE NEOGENESIS PATENT RIGHTS OR THE CUSTOMER
PATENT RIGHTS, OR SUCH PARTY'S OBLIGATIONS UNDER THIS AGREEMENT.

     (b) THE REPRESENTATIONS AND WARRANTIES OF EACH OF NeoGenesis AND CUSTOMER
EXTEND ONLY TO THE OTHER PARTY. NEITHER PARTY WILL BE LIABLE FOR ANY CLAIM OR
DEMAND AGAINST SUCH OTHER PARTY BY A THIRD PARTY, EXCEPT TO THE EXTENT PROVIDED
IN SECTIONS 7.1-7.2.

7.   INDEMNIFICATION

7.1  INFRINGEMENT INDEMNIFICATION. (a) Subject to the provisions of Section 7.4,
NeoGenesis shall defend, indemnify and hold harmless CUSTOMER, its subsidiaries,
parent corporations, Affiliates, officers, directors, independent contractors,
partners, sublicensees, distributors, members, employees, agents, successors and
assigns (each, in such capacity, an INDEMNIFIED PARTY) from and against any
claim, suit, demand, loss, damage, expense (including reasonable

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       25
<Page>

attorney's fees of indemnitee(s) and those that may be asserted by a third
party) or liability (collectively, LOSSES) imposed upon them by any third party
and arising from or related to a third party claim that (i) use of NeoGenesis
Know-How or (ii) practice of the NeoGenesis Patent Rights by CUSTOMER in
accordance with the terms of this Agreement violates or infringes the
intellectual property rights of any third party. NeoGenesis shall have no
liability or obligation to CUSTOMER under this Section 7.1(a) in the event and
to the extent that the alleged infringement is caused by: (1) modifications,
alterations, combinations or enhancements of the Designated Compounds not
created by NeoGenesis, or (2) or results from willful misconduct or negligent
acts or omissions of CUSTOMER or its Affiliates, or its or their respective
employees, officers, directors or agents.

     (b) Subject to the provisions of Section 7.3, CUSTOMER shall defend,
indemnify and hold harmless NeoGenesis, its subsidiaries, parent corporations,
Affiliates, officers, directors, independent contractors, partners,
shareholders, employees, agents, successors and assigns (each, in such capacity,
an INDEMNIFIED PARTY) from and against any Losses imposed upon them by any third
party and arising from or related to a third party claim that (i) the use of the
CUSTOMER Know-How; (ii) the practice of the CUSTOMER Patent Rights; and (iii)
the Manufacture, development, testing, Commercialization, use or other
disposition of any of the foregoing, violates or infringes the intellectual
property rights of any third party. CUSTOMER shall have no obligation or
liability to NeoGenesis under this Section 7.1(b) in the event and to the extent
that the alleged infringement (1) is covered by Section 7.1(a) or (2) results
from willful misconduct or negligent acts or omissions of NeoGenesis or its
Affiliates, or its or their respective employees, officers, directors or agents.

7.2  OTHER CLAIMS. (a) Subject to the provisions of Section 7.3, NeoGenesis will
defend, indemnify and hold harmless the CUSTOMER Indemnified Parties from and
against any Losses imposed upon the Indemnified Party(s) by any third party
arising from or related to: (i) any material breach of the NeoGenesis's
representations and warranties under this Agreement; or (ii) any negligence or
intentional misconduct by NeoGenesis (or its employees, agents or
representatives) in performing its obligations under this Agreement, including
the performance of the Program. The foregoing indemnification action shall not
apply in the event and to the extent that such Losses arose as a result of any
Indemnified Party's negligence, intentional misconduct or breach of this
Agreement.

     (b) Subject to the provisions of Section 7.3, CUSTOMER will defend,
indemnify and hold harmless the NeoGenesis Indemnified Parties from and against
any Losses imposed upon the Indemnified Party(s) by any third party arising from
or related to: (i) any material breach of CUSTOMER's representations and
warranties under this Agreement; (ii) any negligence or intentional misconduct
by CUSTOMER (or its employees, agents or representatives) or by an Affiliate,
licensee, sublicensee, distributor or agent of CUSTOMER in performing its
obligations under this Agreement, including the performance of the R&D Program;
or (iii) the labeling, packaging, package insert, other materials or promotional
claims with respect to any Licensed Product or the development, testing,
Manufacturing, Commercialization, use or other disposition of any Licensed
Product by CUSTOMER or by an Affiliate, licensee, sublicensee, distributor or
agent of CUSTOMER. The foregoing indemnification action shall not apply in the
event and to

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       26
<Page>

the extent that such Losses arose as a result of any Indemnified Party's
negligence, intentional misconduct or breach of this Agreement.

7.3  PROCEDURE. To receive the benefit of indemnification under Sections 7.1 or
7.2, the Indemnified Party must (a) promptly notify the party from whom
indemnification is sought (the INDEMNIFYING PARTY) in writing of a claim or
suit; PROVIDED, that failure to give such notice shall not relieve Indemnifying
Party of its indemnification obligations except where, and solely to the extent
that, such failure actually and materially prejudices the rights of Indemnifying
Party); (b) provide reasonable cooperation (at the Indemnifying Party's
expense); and (c) tender to the Indemnifying Party (and its insurer) full
authority to defend or settle the claim or suit; PROVIDED that no settlement
requiring any admission by the Indemnified Party or that imposes any material
obligation or loss on the Indemnified Party shall be made without the
Indemnified Party's consent. Neither party has any obligation to indemnify the
other party in connection with any settlement made without the Indemnifying
Party's written consent. The Indemnified Party has the right to participate at
its own expense in the claim or suit and in selecting counsel therefor. The
Indemnified Party shall cooperate with Indemnifying Party (and its insurer), as
reasonably requested, at Indemnifying Party's cost and expense.

7.4  INDEMNIFICATION AS SOLE REMEDY. To the fullest extent permitted by law, the
indemnification provided in this Section 7, subject to the limitations set forth
herein, shall be the exclusive remedy for damages available to any Indemnified
Party.

7.5  LIMITATION OF LIABILITY. EXCEPT FOR INFRINGEMENT OF THE OTHER PARTY'S
INTELLECTUAL PROPERTY RIGHTS OR BREACH OF CONFIDENTIALITY OBLIGATIONS UNDER
SECTION 5 AND EXCEPT AS OTHERWISE PROVIDED IN SECTIONS 7.1-7.4 WITH RESPECT TO
THIRD PARTY CLAIMS, THE AGGREGATE LIABILITY OF EITHER PARTY FOR DIRECT DAMAGES
ARISING OUT OF THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY SHALL BE
LIMITED TO THE AGGREGATE AMOUNT PAID TO (OR PAID BY) SUCH PARTY BY THE OTHER
PARTY AS OF THE DATE SUCH CLAIM IS FINALLY RESOLVED. EXCEPT FOR INFRINGEMENT OF
THE OTHER PARTY'S INTELLECTUAL PROPERTY RIGHTS OR BREACH OF CONFIDENTIALITY
OBLIGATIONS UNDER SECTION 5 AND EXCEPT AS OTHERWISE PROVIDED IN SECTIONS 7.1-7.4
WITH RESPECT TO THIRD PARTY CLAIMS, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO
THE OTHER FOR LOST PROFITS OR SAVINGS OR FOR ANY INDIRECT, INCIDENTAL,
CONSEQUENTIAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES IN CONNECTION WITH THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, HOWEVER CAUSED,
UNDER ANY THEORY OF LIABILITY.

8.   TERM AND TERMINATION

8.1  TERM. This Agreement shall take effect as of the Effective Date and shall
remain in effect until the later of (i) completion of the Program on CUSTOMER'S
[*] Target, if that Target is identified and accepted within four (4) years of
the Effective Date, subject to any extensions

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       27
<Page>

entered into pursuant to Section 2.2, or (ii) until expiration of CUSTOMER's
obligation to pay royalties hereunder if the license under Section 3.1 is
exercised, in each case unless sooner terminated in accordance with Section 8.2.
If the license under Section 3.1 is exercised through the selection of a
Designated Compound for a Target, as described in Section 2.7, such license will
remain in effect until the LATER OF: (a) the expiration of the term of the
last-to-expire of the patent rights within the NeoGenesis Patent Rights or
Program Intellectual Property or (b) [*] following the First Commercial Sale in
the last country in which sales of Licensed Products are made (if the Licensed
Products do not embody any patents within the NeoGenesis Patent Rights or
Program Intellectual Property).

8.2  TERMINATION. (a) Either party may terminate the Program with thirty (30)
days notice to the other party commits a material breach unless the breach is
cured within the thirty (30)-day notice period. In addition, NeoGenesis may
suspend work pursuant to the Program with notice to CUSTOMER if CUSTOMER fails
to pay NeoGenesis any amount due NeoGenesis under this Agreement.

     (b) Following completion of the Program, either party may terminate the
license with sixty (60) days notice if the other commits a material breach
unless the breach is cured within the sixty (60)-day notice period consistent
with Section 8.2(a).

     (c) Either party shall have the right to terminate this Agreement upon
thirty (30) days notice if a Force Majeure condition has prevented performance
by the other party for more than one hundred twenty (120) consecutive days. The
parties may also terminate this Agreement at any time upon mutual written
agreement of the parties.

8.3 EFFECT OF TERMINATION/COMPLETION. (a) Upon termination (including
expiration) of this Agreement or completion of the Program with respect to a
Target: (i) NeoGenesis will terminate all tasks for such Program in an orderly
manner, as soon as practical and in accordance with a schedule agreed to by
CUSTOMER and NeoGenesis; (ii) NeoGenesis shall deliver to CUSTOMER all materials
developed through the termination of such Program; (iii) CUSTOMER shall pay
NeoGenesis any monies due and owing NeoGenesis up to the time of termination,
for services actually performed in respect of such Program (including all
work-in process (if any) pursuant to the last sentence of paragraph 6 or the
last sentence of paragraph 7 of ATTACHMENT A) in an amount calculated using
NeoGenesis's then-current daily charge for similar services and deliverables,
PROVIDED, such fee shall not exceed the price specified in this Agreement and
(iv) within thirty (30) days following termination (including expiration) of
such Program, NeoGenesis shall deliver to CUSTOMER a reasonably-detailed written
report describing the results of all research activities conducted under this
Agreement in respect of such Program up to the date of such termination.

     (b) Upon notice from a disclosing party or termination (including
expiration) of this Agreement each party shall return to the other party or
certify in writing to the other party that it has destroyed all documents and
other tangible items it or its employees or agents have received or created
pertaining, referring or relating to the Confidential Information of the other
party.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       28
<Page>

     (c) The licenses granted by NeoGenesis under Section 3.1 shall survive any
expiration or termination of the Program or this Agreement with respect to any
Designated Compound or Licensed Product for which the applicable service fees
and milestone fees and royalties have been paid (when due in accordance with the
terms of this Agreement) and CUSTOMER shall continue to have the right to
develop, have developed, make, have made, use, distribute, offer for sale,
import, export and sell Licensed Products relating to such Designated Compounds;
PROVIDED that CUSTOMER shall continue to pay NeoGenesis milestone fees and
royalties as required by Sections 4.2 and 4.3 and complies with Sections
4.4-4.7. In the event the license granted to CUSTOMER under Section 3.1
terminates for any reason, each of CUSTOMER's sublicensees at such time shall
continue to have the rights and license set forth in their sublicense
agreements, PROVIDED such sublicensee agrees in writing that NeoGenesis is
entitled to enforce all relevant provisions directly against such sublicensee.

     (d) Except as otherwise provided herein, neither party shall be liable to
the other party for any compensation or damages by reason of termination of this
Agreement in accordance with this Section 8.

     (e) Nothing herein shall be construed to release either party of any
obligation which matured prior to the effective date of any termination.
CUSTOMER's liability for any charges, payments or expenses due to NeoGenesis
that accrued prior to the termination date shall not be extinguished by
termination, and such amounts (if not otherwise due on an earlier date) shall be
immediately due and payable on the termination date. NeoGenesis shall refund
CUSTOMER for any amounts paid prior to termination for activities not performed.

8.4  SURVIVAL. Sections 1, 2.7, 3.1 (solely in accordance with Section 8.3(c)),
3.2, 3.3 and 4-9 shall survive any termination or expiration of this Agreement.

9.   GENERAL PROVISIONS.

9.1  ISSUE RESOLUTION. (a) The parties shall use their best efforts to resolve
any controversy or dispute that arises under or relates to this Agreement
through good faith discussions. The parties shall initiate such discussions
using the following procedure. Either party shall notify the other party of the
nature of the controversy or dispute, providing sufficient detail to permit the
other party to understand same (a DISPUTE NOTICE). The representatives of the
parties shall meet within 30 days after the date that the non-sending party
receives the Dispute Notice to attempt to reach an agreement about the nature of
the dispute and a resolution of the dispute. If they are unable to resolve the
dispute within 60 days after their meeting, and do not agree to extend the time
period for resolving the dispute, or if the terms and conditions of the
resolution or settlement of the dispute are breached, the dispute may be
resolved by litigation. Pending resolution of any dispute covered by this
Section 9.1, both parties will continue their performance under this Agreement
including, without limitation, the payment of all amounts due to the other party
that are not in dispute.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       29
<Page>

9.2  GOVERNING LAW. This Agreement shall be governed and construed in accordance
with the internal, substantive laws of the Commonwealth of Massachusetts to the
exclusion of any choice or conflict of laws rule or provision that would result
in the application of the substantive law of any other jurisdiction.
Notwithstanding the foregoing, the parties (and the arbitrators) shall use
United States (Federal) patent and copyright laws for purposes of governing and
construing Sections 3.2-3.4 of this Agreement. The United Nations Convention on
Contracts for the International Sale of Goods shall not apply to the
transactions contemplated by this Agreement.

9.3  AMENDMENT AND WAIVER. No provision of or right under this Agreement shall
be deemed to have been waived by any act or acquiescence on the part of either
party, its agents or employees, but only by an instrument in writing signed by
an authorized officer of each party. No waiver by either party of any breach of
this Agreement by the other party shall be effective as to any other breach,
whether of the same or any other term or condition and whether occurring before
or after the date of such waiver.

9.4  INDEPENDENT CONTRACTORS. Each party represents that it is acting on its own
behalf as an independent contractor and is not acting as an agent for or on
behalf of any third party. This Agreement and the relations hereby established
by and between CUSTOMER and NeoGenesis do not constitute a partnership, joint
venture, franchise, agency or contract of employment. Neither party is granted,
and neither party shall exercise, the right or authority to assume or create any
obligation or responsibility on behalf of or in the name of the other party or
its Affiliates. NeoGenesis shall be solely responsible for compensating all its
personnel and for payment of all related FICA, workers' compensation,
unemployment and withholding taxes. CUSTOMER shall not provide NeoGenesis
personnel with any benefits, including but not limited to compensation for
insurance premiums, paid sick leave or retirement benefits.

9.5  ASSIGNMENT. Neither party may assign this Agreement or any of its rights
and obligations under this Agreement without the prior written consent of the
other party; PROVIDED, that either party may assign this Agreement to (a) any
Person to which such party transfers all or substantially all of its assets
related to this Agreement or with which such party is consolidated or merged;
(b) any Person that owns a majority of the voting stock of such party; or (c)
any Person of which such party owns directly or indirectly a majority of the
voting stock; PROVIDED, FURTHER, that in each instance the assignee Person
expressly assumes all obligations imposed on the assigning party by this
Agreement in writing and the other party is notified in advance of such
assignment.

9.6  SUCCESSORS AND ASSIGNS. This Agreement shall bind and inure to the benefit
of the parties hereto and their respective successors and permitted assigns.

9.7  NOTICES. Unless otherwise provided herein, any notice, report, payment or
document to be given by one party to the other shall be in writing and shall be
deemed given when delivered personally or mailed by certified or registered
mail, postage prepaid (such mailed notice to be effective on the date which is
three (3) business days after the date of mailing), or sent by nationally
recognized courier for next day delivery (such notice sent by courier to be
effective one business day after it is deposited with such courier), or sent by
facsimile or e-mail (such

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       30
<Page>

notice to be effective when sent, if confirmed by overnight courier as
aforesaid) to the address set forth on the signature page to this Agreement or
to such other place as any party may designate as to itself by written notice to
the other party.

9.8  SEVERABILITY. In the event any provision of this Agreement shall for any
reason be held to be invalid, illegal or unenforceable in any respect, such
invalidity, illegality or unenforceability shall not affect any other term or
provision hereof. The parties agree that they will negotiate in good faith or
will permit a court or arbitrator to replace any provision hereof so held
invalid, illegal or unenforceable with a valid provision which is as similar as
possible in substance to the invalid, illegal or unenforceable provision.

9.9  CAPTIONS. Captions of the sections and subsections of this Agreement are
for reference purposes only and do not constitute terms or conditions of this
Agreement and shall not limit or affect the meaning or construction of the terms
and conditions hereof.

9.10 WORD MEANINGS. Words such as HEREIN, HEREINAFTER, HEREOF and HEREUNDER
refer to this Agreement as a whole and not merely to a section or paragraph in
which such words appear, unless the context otherwise requires. The singular
shall include the plural, and each masculine, feminine and neuter reference
shall include and refer also to the others, unless the context otherwise
requires.

9.11 ENTIRE AGREEMENT. The terms and provisions contained in this Agreement
(including the Attachments) constitute the entire understanding of the parties
with respect to the transactions and matters contemplated hereby and supersede
all previous communications, representations, agreements and understandings
relating to the subject matter hereof. No representations, inducements, promises
or agreements, whether oral or otherwise, between the parties not contained in
this Agreement shall be of any force or effect. No agreement or understanding
extending this Agreement or varying its terms (including any inconsistent terms
in any purchase order, acknowledgment or similar form) shall be binding upon
either party unless it is in a writing specifically referring to this Agreement
and signed by a duly authorized representative of the applicable party.

9.12 RULES OF CONSTRUCTION. The parties agree that they have participated
equally in the formation of this Agreement and that the language and terms of
this Agreement shall not be construed against either party by reason of the
extent to which such party or its professional advisors participated in the
preparation of this Agreement.

9.13 COUNTERPARTS. This Agreement may be executed in multiple counterparts, each
of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. In making proof of this Agreement, it shall not be
necessary to produce or account for more than one such counterpart.

9.14 FORCE MAJEURE. Except as otherwise provided in this Agreement, in the event
that a delay or failure of a party to comply with any obligation created by this
Agreement is caused by a Force

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       31
<Page>

Majeure condition, that obligation shall be suspended during the continuance of
the Force Majeure condition.

9.15 FURTHER ASSURANCES. Each party covenants and agrees that, subsequent to the
execution and delivery of this Agreement and without any additional
consideration, it will execute and deliver any further legal instruments and
perform any acts which are or may become reasonably necessary to effectuate the
purposes of this Agreement.

     IN WITNESS WHEREOF the parties have caused this Agreement to be executed on
their behalf by their duly authorized representatives intending it to take
effect as an instrument under seal as of the Effective Date.

NEOGENESIS DRUG DISCOVERY, INC.              BIOGEN, INC.

BY:   /s/ SATISH JINDAL                      BY:   /s/ (KEES BEEN)
---------------------------------            ------------------------------
Satish Jindal,  President and CSO            --------------, --------------
NOTICE ADDRESS:                              NOTICE ADDRESS:
NeoGenesis Drug Discovery, Inc.              Biogen, Inc.
840 Memorial Drive                           14 Cambridge Center
Cambridge, MA 02139                          Cambridge, MA 02142
Phone:   617.868.1500                        Phone: 617.679.2000
Fax:     617.868.1515                        Fax:  617.679.2617

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       32<Page>

                                                                   Exhibit 10.10

                                    AGREEMENT
This Agreement (AGREEMENT) is entered into as of July 4, 2001 (EFFECTIVE DATE)
between NeoGenesis Drug Discovery, Inc., a Delaware corporation (NEOGENESIS) and
Mitsubishi-Tokyo Pharmaceuticals, Inc. (MITSUBISHI), a corporation organized
under the laws of Japan, and sets forth the terms and conditions that will apply
to the provision by NeoGenesis to Mitsubishi of certain screening and analysis
services.

                                   BACKGROUND
Mitsubishi is interested in identifying potential pharmaceutical products for
treatment of certain human diseases and wishes to identify compounds that
exhibit a high degree of chemical binding and functional activity to specific
protein targets. NeoGenesis has certain technology and know-how, including
screening processes of libraries of mass-encoded small molecule compounds,
relating to the identification, discovery, validation and optimization of novel
compounds which may be useful for development of novel therapeutics employing
targets implicated in a disease process. The parties wish to pursue a
collaborative screening process to identify compounds exhibiting a high degree
of chemical binding activity to targets designated by Mitsubishi from among the
NeoGenesis libraries of mass-encoded small molecule compounds and which have
activity in bioassays or functional assays. The terms and conditions set forth
below shall govern the performance of such collaborative effort.

1.   DEFINITIONS.
1.1  DEFINED TERMS. Capitalized terms used in this Agreement and not otherwise
defined herein shall have the meaning set forth below.

     AFFILIATE means with respect to either party, any Person that, directly or
indirectly, is controlled by, controls or is under common control with such
party. For purposes of this definition, CONTROL means, with respect to any party
hereto, the direct or indirect ownership of more than [*] of the voting or
income interest in such party or the possession otherwise, directly or
indirectly, of the power to direct the management or policies of such party.

     ALIS means the Automated Ligand Identification System, an automated,
ultra-high throughput ligand selection system proprietary to NeoGenesis that is
used to identify multiple classes of chemical ligands against target protein.

     APPLICABLE LAWS means all laws, statutes, regulations and ordinances of any
Regulatory Authority, including without limitation the FD&C Act.

     CHEMOTYPE means a family or group of related Candidate Compound A (as
defined in ATTACHMENT A).

     CIP means "Carriage and Insurance Paid", as that expression is defined in
INCOTERMS 2000, ICC Publishing S.A.

     COMMERCIALLY REASONABLE EFFORTS means, with respect to (i) any objective by
any party, reasonable, diligent, good faith efforts to accomplish such objective
as such party would normally use to accomplish a similar objective under similar
circumstances; and (ii) with respect to any objective relating to the
development or Commercialization of any Licensed Product by any party efforts
and resources normally used by such party with respect to a product owned by
such party or to which such party has similar rights which is of similar market
potential at a similar stage in the development or life of such product, taking
into account issues of safety, efficacy, product profile, the competitiveness of
the marketplace, the proprietary position of the product, the regulatory
structure involved, profitability of the product and other relevant commercial
factors.

     COMMERCIALIZATION means any and all activities of using, importing,
exporting, marketing, promoting, distributing, offering for sale and selling a
Licensed Product. When used as a verb, COMMERCIALIZE means to engage in
Commercialization.

     CONFIDENTIAL INFORMATION means any proprietary or confidential information
of either party (including but not limited to all Mitsubishi Know-How and all
NeoGenesis Know-How) disclosed to the other party pursuant to this Agreement in
written or other tangible medium and marked as confidential, or if disclosed
orally or displayed, confirmed in writing within thirty (30) days of
disclosure, except any portion thereof which: (i) is known to the receiving
party, as evidenced by the receiving party's written records, before receipt
thereof under this Agreement;

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                        1
<Page>

(ii) is disclosed to the receiving party by a third person who is under no
obligation of confidentiality to the disclosing party hereunder with respect to
such information and who otherwise has a right to make such disclosure; (iii) is
or becomes generally known in the trade through no fault of the receiving party;
or (iv) is independently developed by the receiving party, as evidenced by the
receiving party's written records, without access to such information.

     CONTROL OR CONTROLLED means with respect to any (a) item of information,
including, without limitation, Mitsubishi Know-How and NeoGenesis Know-How, or
(b) intellectual property right, the possession (whether by ownership or
license, other than pursuant to this Agreement) by a party or an Affiliate
thereof of the ability to grant to the other party access or a license as
provided herein under such item or right without violating the terms of any
agreement or other arrangements, between such party or its Affiliate and any
third party, existing before or after the Effective Date.

     DERIVATIVE COMPOUNDS means any derivatives or analogs for a Designated
Compound, which have an IC(50) value against the Target of [*] or less, which
(a) results from a chemical synthesis program based on the Designated Compounds
or (b) is based on structure-activity data of the Designated Compound; PROVIDED,
that any such program or data is in respect of a target protein that is greater
than [*] homologous at the peptide level to the Target for which Mitsubishi
designated such Designated Compound.

     FDA means the United States Food and Drug Administration, or any successor
thereto.

     FD&C ACT means the United States Federal Food, Drug and Cosmetic Act of
1938, as amended.

     FIELD means treatment of any disease in humans.

     FIRST COMMERCIAL SALE of Licensed Product(s) means any transfer for value
in an arms-length transaction to an independent third party distributor, agent
or end user in a country within the Territory after obtaining all necessary
Regulatory Approvals as may be necessary for such transfer in such country.

     FORCE MAJEURE means any event beyond the control of the parties, including,
without limitation, failures of computers, computer-related equipment, hardware
or software, fire, flood, riots, strikes, epidemics, war (declared or undeclared
and including the continuance, expansion or new outbreak of any war or conflict
now in existence), embargoes and governmental actions or decrees.

     GOOD CLINICAL PRACTICE means the then current standards for clinical trials
for pharmaceuticals, as set forth in the FD&C Act and applicable regulations
promulgated thereunder, as amended from time to time, and such standards of good
clinical practice as are required by the European Union and other Regulatory
Authorities in countries in which the Product is intended to be sold, to the
extent such standards are not in contravention with United States Good Clinical
Practices.

     GOOD LABORATORY PRACTICE means the then current standards for laboratory
activities for pharmaceuticals, as set forth in the FD&C Act and applicable
regulations promulgated thereunder, as amended from time to time, and such
standards of good laboratory practice as are required by the European Union and
other Regulatory Authorities in countries in which the Product is intended to be
sold, to the extent such standards are not in contravention with United States
Good Laboratory Practices.

     GOOD MANUFACTURING PRACTICE means the current standards for the manufacture
of pharmaceuticals, as set forth in the FD&C Act and applicable regulations
promulgated thereunder, as amended from time to time, and such standards of good
manufacturing practice as are required by the European Union and other
Regulatory Authorities in countries in which the Product is intended to be sold,
to the extent such standards are not in contravention with United States Good
Manufacturing Practices.

     IND means an investigational new drug application, as defined in the FD&C
Act and applicable regulations thereunder, or any equivalent document, filed
with the FDA and necessary for beginning clinical trials of any Licensed Product
in humans or any application or other documentation filed with any Regulatory
Authority of a

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       2
<Page>

country other than the United States prior to beginning clinical trials of any
Licensed Product in humans in that country.

     JOINT PROGRAM PATENT RIGHTS means any Program Patent Rights (defined in
below) which are jointly owned by the parties in accordance with Section 3.2(a)
and are not Mitsubishi Assigned Patent Rights (defined in below).

     LICENSED PRODUCT(S) means any product: (a) which includes a Designated
Compound or a Derivative Compound; and (b) the development, manufacture, use, or
sale of which, absent the license granted to Mitsubishi under Section 3.1 or the
rights assigned to Mitsubishi under Section 3.2(d) of this Agreement, would
infringe the NeoGenesis Know-How, NeoGenesis Patent Rights, or which makes use
of any Program Patent Rights that is jointly owned by the parties.

     MAJOR COUNTRY mean the United States, the United Kingdom, France, Germany,
Italy or Japan, as the case may be.

     MANUFACTURING means any and all activities involved in the production of a
Licensed Product to be developed and/or Commercialized under this Agreement.
When used as a verb, MANUFACTURE means to engage in Manufacturing.

     MITSUBISHI ASSIGNED KNOW-HOW means a part of Mitsubishi Know-How which is
assigned by NeoGenesis to Mitsubishi in accordance with Section 3.2(d).

     MITSUBISHI ASSIGNED PATENT RIGHTS means a part of Mitsubishi Patent Rights
which is assigned by NeoGenesis to Mitsubishi in accordance with Section 3.2(d).

     MITSUBISHI KNOW-HOW means all proprietary technical, Manufacturing and
clinical information, data and know-how, including but not limited to any
intellectual property relating to: (a) the Target, (b) the Derivative Compounds
or (c) the Licensed Products containing the Derivative Compounds, whether or not
patentable, Controlled by Mitsubishi or its Affiliates as of the Effective Date
or during the term of this Agreement. Mitsubishi Know-How includes, without
limitation, all processes, formulas, discoveries and inventions whether relating
to biological, chemical, pharmacological, toxicological, pharmaceutical,
physical and analytical safety, quality control and clinical data, including,
without limitation, clinical study data. Mitsubishi Know-How also includes
relevant medical information relating to the Licensed Products (such as customer
questions, responses thereto and adverse drug event) history in the possession
of Mitsubishi, its Affiliates or sublicensees. The term Mitsubishi Know-How,
however, does not include the NeoGenesis Know-How or any know-how, processes,
information and data which is, as of the Effective Date or later becomes,
generally available to the public.

     MITSUBISHI PATENT RIGHTS means (a) those patents and patent applications
(other than patent applications and patents included within the NeoGenesis
Patent Rights) Controlled by Mitsubishi at any time during the term of this
Agreement which (i) relate to or otherwise would be infringed by the
manufacture, use, importation or sale of any Designated Compound or Licensed
Product or (ii) relate to Mitsubishi Know-How and (b) all divisionals,
continuations, continuations-in-part, reissues, extensions, supplementary
protection certificates and foreign counterparts thereof.

     NDA means a new drug application as defined in the FD&C Act and applicable
regulations thereunder, and the non-U.S. equivalent thereof.

     NEOGENESIS KNOW-HOW means all proprietary technical information, data and
know-how, including but not limited to any intellectual property relating to:
(a) the NeoMorph Screening Library, (b) the NeoMorph Focused Libraries, (c) ALIS
and QSCD, (d) the Candidate Compound A, (e) the Candidate Compound B, (d) the
Candidate Compound C, together with, where applicable, any analogs, derivatives,
fragments, sub-cellular constituents or expression products thereof and (e) any
other tangible materials provided by NeoGenesis to Mitsubishi for use in the
conduct of the Program, which (i) is Controlled by NeoGenesis, (ii) primarily
relates to a Designated Compound or Licensed Products, whether or not
patentable, and (iii) is listed in ATTACHMENT D, as ATTACHMENT D is amended from
time to time in accordance with Section 2.6 or Section 3.3. The term NeoGenesis
Know-How, HOWEVER, does not

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       3
<Page>

include (1) any Mitsubishi Know-How, (2) any know-how, processes, information
and data which is, as of the Effective Date or later becomes,
generally available to the public or (3) any general manufacturing or other
know-how not specific to the Designated Compound or Licensed Products.

     NEOGENESIS PATENT RIGHTS means those (a) patents and patent applications
listed in ATTACHMENT D, as ATTACHMENT D is amended from time to time in
accordance with Section 2.6 or Section 3.3, which are Controlled by NeoGenesis;
and (b) all divisionals, continuations, continuations-in-part, reissues,
extensions, supplementary protection certificates and foreign counterparts
thereof which are Controlled by NeoGenesis and are existing as of the Effective
Date or filed or issued during the term of this Agreement.

     NEOMORPH CHEMISTRY means the process, proprietary to NeoGenesis, of forming
libraries and sub-libraries of discrete compounds by coupling a broad set of
diverse cores with diverse sets of building blocks employing proprietary
mass-coding algorithms.

     NEOMORPH FOCUSED LIBRARIES means those compounds synthesized by NeoGenesis
derived from Active Compounds identified by Mitsubishi in bioassays or
functional assays

     NEOMORPH SCREENING LIBRARY means the entire collection of libraries
consisting of mass-encoded small molecule organic compounds owned by NeoGenesis
and developed with NeoMorph Chemistry, comprising at least 10,000,000 different
compounds.

     NET SALES means the aggregate amounts invoiced for sales or transfers for
value of Licensed Products by Mitsubishi, its Affiliates or any of its
sublicensee to an independent third party distributor, agent or end user in the
Territory (other than sales of Licensed Products at cost by Mitsubishi, its
Affiliates or sublicensees to a third party for use in a clinical study prior to
Regulatory Approval of such Licensed Product) LESS deductions selected as
appropriate from: (a) credits, refunds, allowances and price adjustments
separately and actually credited to customers for defective, spoiled, damaged,
outdated, and returned Licensed Products, (b) offered and taken trade and cash
discounts and rebates in amounts customary to the trade and as required to do
business in the country in which they are made, (c) sales, excise, value added,
turnover, use, and other like taxes, and customs duties, paid, absorbed or
allowed excluding net income tax, and (d) special outbound packing,
transportation, insurance and handling charges separately billed to the customer
or prepaid. Net Sales shall not include revenue received by Mitsubishi (or any
of its Affiliates) from transactions with an Affiliate, where the Licensed
Product in question will be resold to an independent third-party distributor,
agent or end user by the Affiliate where such revenue received by the Affiliate
from such resale is included in Net Sales in accordance with Section 4.3.
Revenue received by Mitsubishi (or any of its Affiliates) from transactions with
an Affiliate, where the Licensed Product in question is used by the Affiliate
solely for such Affiliate's internal purposes shall also be included in Net
Sales at a price equal to the fair market value of such transfer(s).

     PERSON means any individual, corporation, association, partnership (general
or limited), joint venture, trust, estate, limited liability company, limited
liability partnership, unincorporated organization, government (or any agency or
political subdivision thereof) or other legal entity or organization.

     PROGRAM means the screening program described in ATTACHMENT A as the same
may be amended during the term of this Agreement by mutual agreement of the
parties. The Program will be directed toward the discovery and development of
Candidate Compound B and Candidate Compound C for the Targets.

     PROGRAM INTELLECTUAL PROPERTY means individually and collectively all
discoveries, inventions, know-how, techniques, methodologies, modifications,
improvements, works of authorship, designs and data (whether or not protectable
under patent, copyright, trade secrecy or similar laws) that are conceived,
created, discovered, developed, or reduced to practice or tangible medium of
expression (a) solely by one or more employees or consultants of NeoGenesis
(other than consultants also affiliated with Mitsubishi in connection with the
Program) at any time in the course of the Program; (b) jointly by one or more
employees or consultants of NeoGenesis and one or more employees or consultants
of Mitsubishi at any time in the course of the Program; or (c) solely by one or
more employees or consultants of Mitsubishi (other than consultants also
affiliated with NeoGenesis in connection with the

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       4
<Page>

Program) at any time in the course of the Program. Program Intellectual Property
is listed in ATTACHMENT B, which shall be amended from time-to-time to
include new Program Intellectual Property, in accordance with Section 3.3.

     PROGRAM PATENT RIGHTS means (a) those patents and patent applications, the
claim of which covers all or part of Program Intellectual Property, and (b) all
divisionals, continuations, continuations-in-part, reissues, extensions,
supplementary protection certificates and foreign counterparts thereof.

     QSCD means Quantisized Surface Complimentary Diversity, a model proprietary
to NeoGenesis, in terms of which discrete chemical compliments to the surfaces
of a Target are defined.

     R&D PROGRAM means on a Designated Compound-by-Designated Compound or
Licensed Product-by-Licensed Product and country-by-country basis the activities
necessary or desirable to be undertaken in connection with the research and
development of such Designated Compound or Licensed Product prior to obtaining
Regulatory Approval for a Licensed Product in such country (regardless of the
country in which such activities are conducted).

     REGULATORY APPROVALS means, for any country in the Territory, those
authorizations by the appropriate Regulatory Authority(ies) required for the
manufacture, importation, marketing, promotion, pricing and sale of the Licensed
Product(s) in such country.

     REGULATORY AUTHORITY means any national, supra-national, regional, state or
local regulatory agency, department, bureau, commission, council or other
governmental entity in the Territory, including, without limitation, the FDA.

     SUCCESS CRITERIA means the success criteria defined by the parties with
respect to Candidate Compound C that have a certain desired degree of chemical
binding activity and activity in Target-based functional assays.

     TARGET means a specific protein target(s) selected by Mitsubishi for which
NeoGenesis will perform the Program. The Target(s) are identified in ATTACHMENT
C.

     TERRITORY means all the countries of the world.

1.2  OTHER DEFINED TERMS.  The following terms shall have the meanings set forth
in the section appearing opposite such term:

<Table>
         <S>                                         <C>
         AGREEMENT                                   Recitals
         BANKRUPTCY CODE                             Section 3.1
         CANDIDATE COMPOUNDS A                       ATTACHMENT A
         CANDIDATE COMPOUND B                        ATTACHMENT A
         CANDIDATE COMPOUNDS C                       ATTACHMENT A
         CLAIM NOTICE                                Section 6.6
         COMPOUNDS                                   ATTACHMENT A
         DESIGNATED COMPOUND                         Section 2.6
         EFFECTIVE DATE                              Recitals
         FDA                                         Section 4.2
         ICC                                         Section 9.1
         INDEMNIFYING PARTY                          Section 7.4
         INDEMNIFIED PARTY(IES)                      Section 7.3
         FINAL TARGET REPORT                         ATTACHMENT A
         LICENSED TECHNOLOGY                         Section 3.1
         LOSSES                                      Section 7.2
         MITSUBISHI                                  Recitals
         NEOGENESIS                                  Recitals
         PHASE I CLINICAL TRIALS                     Section 4.2
         PHASE III CLINICAL TRIALS                   Section 4.2
         PMA                                         Section 4.2
         SCREENING PERIOD                            Section 2.2
</Table>

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       5
<Page>

2.   SCREENING PROGRAM; R&D PROGRAM; COMMERCIALIZATION
2.1  DELIVERY OF TARGET PROTEINS. Mitsubishi shall deliver the Targets to
NeoGenesis for screening within [*] following the Effective Date. Mitsubishi
shall provide Targets in the quantities and formats specified in ATTACHMENT A.
Mitsubishi shall also provide NeoGenesis at the time of delivery with a written
description of the concentration and volume of the Target. Mitsubishi shall
deliver the Targets CIP to NeoGenesis's Cambridge facility.

2.2  SCREENING PROGRAM. NeoGenesis will apply use its ALIS method to screen the
NeoMorph Library for activity with respect to each Target for purposes of
identifying potentially useful chemical compounds for further evaluation and
development. Screening will be performed pursuant to the screening protocol for
the Program set forth in ATTACHMENT A. NeoGenesis shall commence the Program
following the date the Targets are delivered to NeoGenesis and shall complete
the Program within [*] following the date that the Targets are delivered to
NeoGenesis, unless the parties agree in writing to extend the period for
performance of the Program (the SCREENING PERIOD).

2.3  GRANT OF RESEARCH LICENSE. Mitsubishi hereby grants NeoGenesis a
nonexclusive, nontransferable, royalty-free license to use Mitsubishi Know-How
and Mitsubishi Patent Rights solely for purposes of conducting the Program and
performing NeoGenesis's obligations to Mitsubishi under the Program. NeoGenesis
will not use Mitsubishi Know-How or Mitsubishi Patent Rights for any other
purpose, without Mitsubishi's prior written permission. NeoGenesis shall not (a)
grant, or attempt to grant, a sub-license to use Mitsubishi Know-How or
Mitsubishi Patent Rights to any Person without the express written consent of
Mitsubishi, (b) perform any tests on either of the Targets that are outside the
scope of the Program, or (c) modify the Targets supplied by Mitsubishi,
including, without limitation, the making of any derivatives, analogs or
components thereof. In the event that NeoGenesis does not consume all of the
Targets supplied by Mitsubishi in performance of the Program, NeoGenesis will
upon completion of the Program promptly, return to Mitsubishi any quantities of
such Target(s) and any derivatives, analogs or components thereof.

2.4  SCIENTIFIC REPORTS. (a) NeoGenesis will keep and maintain adequate records
containing laboratory data generated in the course of the Program to enable it
to furnish complete and accurate information to Mitsubishi regarding the Program
activities and results, including all Candidate Compound A, Candidate Compound B
and NeoMorph Focused Libraries identified in the Program and all Program
Intellectual Property developed by NeoGenesis during the Program. All such
written records of NeoGenesis shall be open to inspection by Mitsubishi during
normal business hours upon reasonable prior written notice.

     (b)  NeoGenesis shall provide Mitsubishi with reasonably-detailed written
reports describing the results of the research performed pursuant to the Program
including all Candidate Compound A, Candidate Compound B and NeoMorph Focused
Libraries identified in the Program. Such reports shall be delivered to
Mitsubishi at least monthly during the Program. NeoGenesis will deliver a Final
Target Report (as defined in ATTACHMENT A) with respect to the Program work
performed on each Target including a description of all the Candidate Compound
A, Candidate Compound B and NeoMorph Sublibraries identified during the Program
with respect to such Target.

2.5  COMMUNICATIONS. The parties shall meet or communicate from time to time
each other to conduct the Program. The parties shall designate a representative
who shall be in charge of the communication between parties during a period of
the Program. Mitsubishi shall have the right to make the final decision with
respect to the management and conduct the Program after the communication or
discussion between the parties.

2.6  DESIGNATED COMPOUNDS. (a) Within [*] following the delivery of the Final
Target Report for each Target by NeoGenesis in accordance with Section 2.4 and
ATTACHMENT A, Mitsubishi shall notify NeoGenesis whether it will classify any
Candidate Compound C (or any derivative compound(s) of such Candidate Compound
C) as candidates for drug development based on Mitsubishi's good faith
evaluation of the satisfaction of the Success Criteria by such Candidate
Compound C (or any derivative compound(s) of such Candidate Compound C) (each, a
DESIGNATED COMPOUND). Mitsubishi may select [*] Designated Compounds for each
Target. If Mitsubishi does not identify any Designated Compound(s) within such
period, then upon [*] notice from NeoGenesis and unless Mitsubishi identifies

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       6
<Page>

such Designated Compound(s) within such [*] period, the license granted
Mitsubishi shall terminate and be of no further force or effect with respect to
the applicable Target, and no further payment from Mitsubishi shall be due with
respect to such Target.

     (b) Within [*] following receipt of notification from Mitsubishi
identifying Designated Compounds, NeoGenesis shall amend ATTACHMENT D to
identify any applicable NeoGenesis Patent Rights not previously identified to
Mitsubishi.

2.7  PRODUCT DEVELOPMENT. Mitsubishi, at its sole expense, shall be solely
responsible for conducting the R&D Program related to Designated Compounds and
Licensed Products and shall use its Commercially Reasonable Efforts to develop
and obtain Regulatory Approvals for Licensed Products in at least one of the
Major Countries. Mitsubishi shall conduct the R&D Program in accordance with all
Applicable Laws, Good Laboratory Practices and Good Clinical Practices.

2.8  MANUFACTURE OF PRODUCT. Mitsubishi shall be solely responsible, at its sole
expense, for and shall use its Commercially Reasonable Efforts to Manufacture
the Licensed Products in accordance with the Regulatory Approvals, Applicable
Laws, Good Laboratory Practices and Good Manufacturing Practices.

2.9  REGULATORY MATTERS. Mitsubishi shall be solely responsible, at its sole
expense, for the preparation and filing, in its own name or in the name of a
sublicensee (if Mitsubishi sublicenses its rights under Section 3.1), with the
appropriate Regulatory Authorities, of all documents that are necessary to
conduct clinical studies of Licensed Products and Regulatory Approval
applications that are necessary to market and sell Licensed Products. Mitsubishi
shall use Commercially Reasonable Efforts to file Regulatory Approval
applications in the Major Countries. Simultaneously with the submission of each
such regulatory filing, Mitsubishi shall notify NeoGenesis, in writing, that
such regulatory filing has been made. Mitsubishi shall be solely responsible for
reporting all adverse events associated with any Licensed Product to the
appropriate Regulatory Authorities in accordance with Applicable Laws.

2.10 MARKETING AND SALE. Mitsubishi, at its sole expense, shall be solely
responsible for the Commercialization of Licensed Products in the Territory and
shall use its Commercially Reasonable Efforts to Commercialize each Licensed
Product in at least one of the Major Countries. Mitsubishi shall be solely
responsible for establishing the price of each Licensed Product sold by or on
behalf of it pursuant to this Agreement.

2.11 THIRD PARTY LICENSES. Mitsubishi shall be solely responsible for (a)
obtaining any and all licenses from third parties necessary or desirable to
perform the R&D Program and/or to Commercialize any Licensed Product and (b) any
and all consideration payable with respect to such licenses.

2.12 COMPLIANCE WITH LAW. Mitsubishi shall conduct the R&D Program and conduct
its Manufacturing operations in a safe and prudent manner, in compliance with
all Applicable Laws (including, but not limited to, occupational safety and
health, public safety and health, protecting the environment, the disposal of
wastes, Good Clinical Practices, Good Laboratory Practices and Good
Manufacturing Practices), and in compliance with all applicable provisions of
this Agreement. Mitsubishi shall obtain all necessary registrations and permits
pertaining to activities contemplated by this Agreement.

2.13 PERIODIC REVIEW. Mitsubishi shall periodically, at least once a year,
provide NeoGenesis with an update on the status of the progress of Mitsubishi's
R&D Program and Commercialization of each Licensed Product.

3.   LICENSE; PROPRIETARY RIGHTS
3.1  GRANT OF LICENSE. (a) Subject to the terms and conditions of this
Agreement, including the payment of all applicable fees, NeoGenesis hereby
grants to Mitsubishi, and Mitsubishi hereby accepts, an exclusive, worldwide,
right and license, within the Territory, to use the NeoGenesis Know-How and
NeoGenesis Patent Rights and NeoGenesis' undivided interest in any Program
Intellectual Property and Joint Program Patent Rights, as embodied in or related
to any Designated Compound(s) (collectively, the LICENSED TECHNOLOGY), to (i)
research, develop, make, have made and use such Designated Compound to develop
Licensed Products and (ii) to make, have made, use, distribute for sale,
promote, market, offer for sale, sell, have sold, import and export Licensed
Products.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                        7
<Page>

Mitsubishi may grant sublicenses of its rights under this Section 3.1; PROVIDED
that Mitsubishi: (1) obtains each sublicensee's written agreement to be subject
to the same obligations as is Mitsubishi under Sections 2.12, 2.13, 3.1(c), 3.2,
4.4-4.7, 5.2 and 8.3(c) (last sentence) of this Agreement (or substantially
identical provisions) and (2) shall remain responsible for the performance of
all of its obligations under this Agreement, whether such obligations are
performed by Mitsubishi, its Affiliates or any of its sublicensees. Mitsubishi
shall also ensure that all sublicensees are required to indemnify NeoGenesis
with respect to the matters that are addressed in Section 7.2(b) and Section
7.3(b) (it being further understood that NeoGenesis need not be identified by
name). For purposes of clarity, it is expressly understood and agreed that in
the event and to the extent that any NeoGenesis Know-How or NeoGenesis Patent
Rights (including NeoGenesis' undivided interest in any Program Intellectual
Property and Joint Program Patent Rights) are the subject of the assignment
under Section 3.2(d), this Section 3.1(a) shall not apply to such NeoGenesis
Know-How or NeoGenesis Patent Rights (including Program Intellectual Property
and Joint Program Patent Rights).

     (b) The license granted under this Section 3.1 shall be treated as a
license of rights to "intellectual property" (as defined in Section 101(56) of
Title 11 of the United States Code, as amended (the BANKRUPTCY CODE)) for
purposes of Section 365(n) of the Bankruptcy Code. The parties agree that
Mitsubishi may elect to retain and may fully exercise all of its rights and
elections under the Bankruptcy Code PROVIDED, that it abides by the terms of
this Agreement.

     (c) Mitsubishi shall mark or have marked all containers or packages of
Licensed Products that are the subject of the license granted under this Section
3.1 in accordance with the patent marking laws of the jurisdiction in which such
Licensed Products are manufactured, used or sold.

3.2  RETAINED RIGHTS. (a) This Agreement does not convey to Mitsubishi any
ownership rights in any NeoGenesis Know-How or NeoGenesis Patent Rights by
implication, estoppel or otherwise except for the rights expressly granted in
Section 3.1 and specifically does not convey to Mitsubishi any rights with
respect to ALIS or QSCD. Title to the NeoGenesis Know-How and NeoGenesis Patent
Rights shall at all times remain vested in NeoGenesis. This Agreement does not
convey to NeoGenesis any ownership rights in any Mitsubishi Know-How or
Mitsubishi Patent Rights by implication, estoppel or otherwise except for the
rights expressly granted in Section 2.3. Unless otherwise provided herein, title
to the Mitsubishi Know-How and Mitsubishi Patent Rights shall at all times
remain vested in Mitsubishi. Title to and any interest in Program Intellectual
Property described in clause (a) of the Program Intellectual Property definition
(including corresponding Program Patent Rights) shall be the property of
NeoGenesis and is included in the definition of NeoGenesis Know-How or
NeoGenesis Patent Rights, as the case may be. Title to and any interest in
Program Intellectual Property described in clause (b) of the Program
Intellectual Property definition (including corresponding Program Patent Rights)
shall be jointly held by Mitsubishi and NeoGenesis. Title to and any interest in
Program Intellectual Property described in clause (c) of the Program
Intellectual Property definition (including corresponding Program Patent Rights)
shall be the property of Mitsubishi and is included in the definition of
Mitsubishi Know-How or Mitsubishi Patent Rights, as the case may be.

     (b) If required, patent counsel mutually acceptable to the parties and
selected by the parties shall determine inventorship of all Program Intellectual
Property and Program Patent Rights that arises from the transactions
contemplated by this Agreement in accordance with U.S. patent law (and other
U.S. intellectual property law) when determining whether such intellectual
property is (i) Mitsubishi Know-How or Mitsubishi Patent Rights or (ii)
NeoGenesis Know-How or NeoGenesis Patent Rights or (iii) whether Program
Intellectual Property or Program Patent Rights is jointly owned or is owned
solely by NeoGenesis or by Mitsubishi.

     (c) NeoGenesis shall retain the following rights with respect to the
following NeoGenesis Know-How and NeoGenesis Patent Rights and Program
Intellectual Property and Program Patent Rights:
         (i) NeoGenesis shall continue to use its compound screening library to
         screen target proteins for other parties; PROVIDED, that (a) for a
         period of [*] from the date of the notice in which NeoGenesis
         identifies Candidate Compound A, NeoGenesis shall mask the Candidate
         Compound A that are in the Chemotype of the Designated Compound(s)
         relating to such Target from the NeoGenesis NeoMorph Screening Library
         and (b) for a period of [*] from the Effective Date, NeoGenesis shall
         not use its NeoMorph Screening Library to screen a target protein that
         is greater than [*] homologous at the peptide level to the Target for
         itself or other parties.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                        8
<Page>

         (ii) NeoGenesis shall continue to use Candidate Compound B and
         Candidate Compound C that are not selected as Designated Compounds, as
         embodied in focused/optimization libraries developed as part of the
         Program to support NeoGenesis patent applications outside the
         transactions contemplated by the Program.

         (iii) NeoGenesis shall retain all rights and continue to use
         optimization compounds created as part of the Program but not selected
         as Candidate Compound B or Candidate Compound C.

         (iv) NeoGenesis shall retain all rights in and continue to use compound
         libraries that are designed as part of the Program using QSCD or other
         structural information.

     (d) In addition to the license granted under Section 3.1 with respect to
Licensed Technology, effective on Mitsubishi's notice date of Designated
Compounds (as specified in ATTACHMENT A), NeoGenesis hereby assigns and agrees
to assign to Mitsubishi all of NeoGenesis' right, title and interest in any and
all Designated Compounds including any patent rights or other intellectual
property rights embodied in or relating to such Designated Compounds within
Program Patent Rights or Program Intellectual Property. Such assigned Designated
Compounds and the corresponding Mitsubishi Assigned Patent Rights shall, from
the date of assignment by NeoGenesis, be treated as Mitsubishi Patent Rights for
purposes of this Agreement (including Section 3.3(d) and Section 3.4) and such
assigned Designated Compounds and the corresponding Mitsubishi Assigned Know-How
shall, from the date of assignment by NeoGenesis, be treated as Mitsubishi
Know-How and Mitsubishi's Confidential Information; PROVIDED, that
notwithstanding any provision of this Agreement to the contrary, Mitsubishi
shall remain obligated to pay NeoGenesis in respect of all such assigned
Designated Compounds (and any related Licensed Products) the milestone fees and
royalties due NeoGenesis under Section 4.2 and Section 4.3 of this Agreement.
NeoGenesis shall cooperate with Mitsubishi with respect to the preparation,
filing and maintenance of Mitsubishi Assigned Patent Rights if Mitsubishi
requires.

3.3  DISCLOSURE; PATENT PROSECUTION. (a) Each of NeoGenesis and Mitsubishi shall
promptly disclose to the other knowledge of any Program Intellectual Property;
such Program Intellectual Property will be added to ATTACHMENT B (and ATTACHMENT
D if applicable) and will be subject to the provisions of this Agreement. Within
forty-five (45) days following the date of such disclosure regarding the
existence of particular Program Intellectual Property that is jointly owned, the
parties shall confer as to appropriate protection for such Program Intellectual
Property. Notwithstanding the provision of this Section 3.3, no party shall
file, prosecute and maintain any Program Patent Right without the other party's
prior written consent before the date specified in ATTACHMENT A for Mitsubishi's
notice of Designated Compounds.

     (b) NeoGenesis shall have the sole right, but not the obligation, to file,
prosecute, and maintain each of the NeoGenesis Patent Rights throughout the
Territory. NeoGenesis shall be responsible for all cost and expenses incurred by
NeoGenesis for the filing, prosecution and maintenance of NeoGenesis Patent
Rights. NeoGenesis shall keep Mitsubishi currently advised as to the status of
all patents and patent applications with respect to the NeoGenesis Patent Rights
and shall supply Mitsubishi promptly with copies of all patents, patent
applications, substantive patent office actions, substantive responses received
or filed in connection with such applications. Mitsubishi may itself or through
its attorney offer comments and suggestions with respect to the matters that are
the subject of this Section 3.3(b) and NeoGenesis agrees to consider such
comments and suggestions; PROVIDED that nothing herein shall obligate NeoGenesis
to adopt or follow such comments or suggestions. In the event that NeoGenesis
elects not to file for patent protection under the NeoGenesis Patent Rights or
elects not to prosecute or maintain a patent or patent application under the
NeoGenesis Patent Rights it shall notify Mitsubishi of such decision at least
forty-five (45) days prior to the due date of any action or payment due.
Mitsubishi shall have the right, but not the obligation, to be assigned such
patents from NeoGenesis and to assume the responsibility therefor then at its
own cost and expense.

     (c) Mitsubishi and NeoGenesis shall discuss Joint Program Patent Rights
issues, and shall select and retain patent counsel mutually acceptable to each
of them, which patent counsel may be Mitsubishi patent counsel or NeoGenesis
patent counsel or third party patent counsel as the parties mutually agree, for
the purpose of preparing, prosecuting, issuing and maintaining appropriate
patent applications concerning Joint Program Patent Rights. Mitsubishi, in
consultation with NeoGenesis, shall be responsible for the preparation, filing
(including foreign filing

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                        9
<Page>

decisions), prosecution and maintenance of such jointly owned Program Patents
Rights. Designated patent counsel shall furnish or have furnished to Mitsubishi
and NeoGenesis copies of documents relevant to the same and provide Mitsubishi
and NeoGenesis with the opportunity to review and comment on patent decisions
made by patent counsel. Any differences between NeoGenesis and Mitsubishi with
respect to preparation, filing, prosecution, issuance and maintenance matters
will be discussed and resolved to their mutual satisfaction using the procedures
specified in Section 9.1, if necessary; PROVIDED, that if any disagreement
regards solely the costs associated with a particular proposed action, either
party may assume responsibility for such costs and the requirement that the
parties mutually agree upon resolution of the matter shall not apply. NeoGenesis
and Mitsubishi shall equally be responsible for all expenses associated with the
preparation, filing, prosecution, issuance and maintenance of Joint Program
Patent Rights; PROVIDED, that in the event that either party elects not to
pursue a particular action with respect to which the parties disagree regarding
costs, the other party shall have the right to assume such costs and to have
such action taken; PROVIDED FURTHER that the rights of the party that does not
pay its portion of such costs shall exclude any intellectual property rights
that are the subject of such action (e.g., patent coverage in a particular
country) unless such party reimburses the other party for one-half (50%) of the
costs of such action.

     (d) Mitsubishi shall have the sole right, but not the obligation, to file,
prosecute, and maintain, at Mitsubishi's sole expense, each of the Mitsubishi
Patent Rights throughout the Territory.

3.4  ENFORCEMENT. (a) NeoGenesis shall be solely responsible for defense and
enforcement of NeoGenesis Know-How and NeoGenesis Patent Rights but excluding
Licensed Technology within the Field and the Territory. Mitsubishi shall be
solely responsible for the defense and enforcement of Mitsubishi Know-How and
Mitsubishi Patent Rights.

     (b) Except as otherwise provided in Section 3.4(a), NeoGenesis shall have
the first option to pursue any enforcement or defense of NeoGenesis Patent
Rights within Licensed Technology ; PROVIDED, that NeoGenesis pays all costs and
expenses related to the same, keeps Mitsubishi reasonably informed of its
progress and provides Mitsubishi with copies of any documents related to such
proceedings and reasonable notice of all proceedings relating to same.
NeoGenesis shall notify Mitsubishi of its decision to exercise its right to
enforce Licensed Technology as soon as possible, but not later than sixty (60)
days following its discovery or receipt of notice of the alleged infringement.

     (c) If NeoGenesis does not exercise its option to enforce or defend any
NeoGenesis Patent Rights within Licensed Technology or (within ninety (90) days
of commencing to prosecute any enforcement or defense action) Mitsubishi and
NeoGenesis have not otherwise agreed not to pursue such infringement for
business reasons, and NeoGenesis (i) has not persuaded the alleged infringer to
desist, (ii) is not diligently pursuing an infringement action or diligently
defending the validity or enforceability of Licensed Technology at issue, as
determined by Mitsubishi in its reasonable discretion, or (iii) has not provided
Mitsubishi with evidence of bona fide negotiations of an acceptable sublicense
agreement with the alleged infringer, then Mitsubishi shall have the right to
pursue the alleged infringer or take control of any action initiated by
NeoGenesis at Mitsubishi's own expense. In any such case, NeoGenesis will
substitute NeoGenesis as party plaintiff for purposes of pursuing any alleged
infringer.

     (d) Any recovery of damages with regard to NeoGenesis Patent Rights within
Licensed Technology in any suit handled by one party pursuant to Section 3.4(b)
or Section 3.4(c) shall be applied first in satisfaction of any unreimbursed
expenses and legal fees of the litigant relating to the suit or settlement
thereof. Any remaining recoveries shall (i) to the extent that the infringement
is based on the development, manufacture, commercialization or use of Licensed
Products in the Field, be deemed Net Sales and NeoGenesis shall receive an
amount equal to the royalty due on such Net Sales and Mitsubishi shall receive
the balance of such remainder; or (ii) to the extent that the infringement is
not based on the development, manufacture, commercialization or use of Licensed
Products in the Field, such remainder shall be paid (1) one hundred percent
(100%) to NeoGenesis if NeoGenesis is the prosecuting party or (2) one hundred
percent (100%) to Mitsubishi if Mitsubishi is the prosecuting party.

     (e) Mitsubishi shall have the first option to pursue any enforcement or
defense of Licensed Technology (other than NeoGenesis Patent Rights); PROVIDED,
that Mitsubishi pays all costs and expenses related to the same, Mitsubishi
keeps NeoGenesis reasonably informed of its progress and Mitsubishi provides
NeoGenesis with copies of any documents related to such proceedings and
reasonable notice of all proceedings relating to same. Mitsubishi

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       10
<Page>

shall notify NeoGenesis of its decision to exercise its right to enforce such
Licensed Technology (other than NeoGenesis Patent Rights) as soon as possible,
but not later than sixty (60) days following its discovery or receipt of notice
of the alleged infringement.

     (f) If Mitsubishi does not exercise its option to enforce or defend any
Licensed Technology (other than NeoGenesis Patent Rights) or (within ninety (90)
days of commencing to prosecute any enforcement or defense action) Mitsubishi
and NeoGenesis have not otherwise agreed not to pursue such infringement for
business reasons, and Mitsubishi has not persuaded the alleged infringer to
desist, then NeoGenesis shall have the right to pursue the alleged infringer or
take control of any action initiated by Mitsubishi at NeoGenesis's own expense.
In any such case, Mitsubishi will substitute NeoGenesis as party plaintiff for
purposes of pursuing any alleged infringer.

     (g) Any recovery of damages with regard to any suit handled by one party
pursuant to Section 3.4(e) or Section 3.4(f) shall be applied first in
satisfaction of any unreimbursed expenses and legal fees of the litigant
relating to the suit or settlement thereof. Any remaining recoveries shall (i)
to the extent that the infringement is based on the development, manufacture,
commercialization or use of Licensed Products in the Field, be deemed Net Sales
and NeoGenesis shall receive an amount equal to the royalty due on such Net
Sales and Mitsubishi shall receive the balance of such remainder; or (ii) to the
extent that the infringement is not based on the development, manufacture,
commercialization or use of Licensed Products in the Field, such remainder shall
be paid (1) one hundred percent (100%) to NeoGenesis if NeoGenesis is the
prosecuting party or (2) one hundred percent (100%) to Mitsubishi if Mitsubishi
is the prosecuting party.

     (h) Notwithstanding the provisions of Section 3.4(b), in the event that a
declaratory judgment action alleging invalidity or non-infringement of any of
the patents within Licensed Technology that are within NeoGenesis Patent Rights
but are not within Joint Program Patent Rights, NeoGenesis shall have the first
option, within sixty (60) days after notification of same, to assume defense of
the action concerning its own technology at its expense, but Mitsubishi shall be
entitled to participate in such action, at its own expense.

     (i) In any infringement suit as either party may institute to enforce
Licensed Technology, Joint Program Patent Rights, Mitsubishi Assigned Patent
Rights, or in any declaratory judgment action alleging invalidity or
non-infringement of any Licensed Technology, Joint Program Patent Rights,
Mitsubishi Assigned Patent Rights brought against NeoGenesis or Mitsubishi, the
other party shall, at the request and expense of the party initiating or
defending the suit or action, cooperate and assist in all reasonable respects,
having its employees testify when requested and making available relevant
records, papers, information, specimens and the like.

     (j) Notwithstanding any provisions of Section 3.4 to the contrary, each
party shall immediately give written notice to the other of any certification of
which it becomes aware filed pursuant to the Waxman-Hatch Act (21 U.S.C.
Sections 355(b)(2)(A), or Sections 355(j)(2)(A)(vii)), or any amendment or
successor statute thereto, at least fourteen (14) days prior to expiration of
the forty five (45) day period set forth in 21 U.S.C. Sections 355(c)(3)(c) (or
any amendment or successor statute thereto), then Mitsubishi shall have the
right to bring such an infringement action, in its sole discretion and at its
own expense, in its own name and/or in the name of NeoGenesis. Any recoveries
obtained (by settlement or otherwise) by either party as a result of any
proceeding against a third party infringer brought under this Section 3.4(j)
shall first be used to reimburse each party for all litigation costs in
connection with such proceeding paid by that party and second, to the extent
that the infringement is based on the development, manufacture,
commercialization or use of Licensed Products in the Field, any remainder shall
be deemed Net Sales and NeoGenesis shall receive an amount equal to the royalty
due on such Net Sales and Mitsubishi shall receive the balance of such
remainder, and, to the extent that the infringement is not based on the
development, manufacture, commercialization or use of Licensed Products in the
Field, any remainder shall be paid (x) one hundred percent (100%) to Mitsubishi
if Mitsubishi is the prosecuting party or (y) one hundred percent (100%) to
NeoGenesis if NeoGenesis is the prosecuting party. If Mitsubishi or its
sublicensee initiate suit pursuant to this Section 3.4(j), it will promptly
notify NeoGenesis.

4.   PRICING; PAYMENT
4.1  SCREENING FEE. Mitsubishi will pay NeoGenesis a screening fee of [*] for
the NeoGenesis services pursuant to the Program. Mitsubishi will pay this fee
within thirty (30) days of the Effective Date.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       11
<Page>

4.2  MILESTONES. (a) Mitsubishi will pay NeoGenesis milestone payments in
respect of Licensed Products as specified in this Section 4.2.

         (i)  Within thirty (30) days following the date on which Mitsubishi
              identifies any Designated Compound in accordance with Section 2.6,
              Mitsubishi will pay NeoGenesis [*].

         (ii) Within thirty (30) days following the date on which Mitsubishi
              administers any Licensed Product to a human subject in the first
              Phase I Clinical Trials relating to any Licensed Product,
              Mitsubishi will pay NeoGenesis [*]. PHASE I CLINICAL TRIALS means
              any safety and/or efficacy clinical studies of any Licensed
              Product in healthy individuals or patients to support its
              continued testing in similar clinical trials prescribed by the
              relevant Regulatory Authority.

         (iii)Within thirty (30) days following the date on which the first
              administration or dosing of any Licensed Product occurs in the
              first Phase III Clinical Trials relating to any Licensed Product,
              Mitsubishi will pay NeoGenesis [*]. PHASE III CLINICAL TRIALS
              means any safety and/or efficacy clinical studies of any Licensed
              Product in human patients with the disease target being studied to
              determine safety and efficacy of a Licensed Product in patients as
              required by the relevant Regulatory Authorities.

         (iv) Within thirty (30) days following the date on which Mitsubishi
              submits a NDA covering any Licensed Product with the FDA, or makes
              a comparable filing with regulatory authorities in another Major
              Country, Mitsubishi will pay NeoGenesis [*].

         (v)  Within thirty (30) days following the date on which Mitsubishi
              receives a product manufacturing approval (PMA) or similar
              Regulatory Approval from the FDA permitting the manufacture and
              sale of a Licensed Product or a comparable Regulatory Approval for
              another Major Country, Mitsubishi will pay NeoGenesis [*].

     (b) Milestones identified in Section 4.2(a)(i)-(iii) shall be due only for
the first Licensed Product, regardless of the number of Licensed Products
identified by the Program or developed and/or commercialized by Mitsubishi.
Milestones identified in Section 4.2(a)(iv)-(v) shall be due for both the first
and the second Licensed Product, regardless of the number of Licensed Products
identified by the Program or developed or Commercialized by Mitsubishi;
PROVIDED, that the payment will not be due in respect of the second Licensed
Product if the second Licensed Product is a replacement for the first Licensed
Product due to the failure of the first Licensed Product to receive a Section
4.2(a)(v) Regulatory Approval. On the date any one milestone with respect to a
Licensed Product is achieved, all lower numbered unachieved milestones shall be
deemed to have been achieved with respect to that Licensed Product.

4.3  ROYALTIES. (a) Not later than sixty (60) days following each March 31, June
30, September 30 and December 31 commencing with the First Commercial Sale of
Licensed Products in any country, Mitsubishi shall pay to NeoGenesis royalties
by country for the most recent three-month period then ended, equal to [*] of
Net Sales. Mitsubishi shall pay royalties with respect to each Licensed Product
on a country by country basis (i) until the expiration or revocation or complete
rejection of the last to expire or to be revoked or to be completely rejected of
any NeoGenesis Patent Right or Joint Program Patent Rights or Mitsubishi
Assigned Patent Rights covering such Licensed Product in the country in which
the Licensed Product is manufactured or sold, or (ii) if no such patent right
exists in the relevant country covering the manufacture, use or sale of the
relevant Licensed Product, until [*] from the First Commercial Sale of such
Licensed Product in such country.

     (b) If Mitsubishi obtains one or more licenses under patents owned by a
third party to avoid infringement by any Licensed Product of such third party
patent(s), Mitsubishi may, beginning from the date of such third party
license, deduct [*] of the amount of royalties paid to such third party on
sales of Licensed Product under such licenses, provided that: (i) such
infringement is primarily due to the Designated Compound as licensed or
assigned by NeoGenesis and not related to changes or additions to the
Designated Compound made by a party other than NeoGenesis and (ii) such
deductions reduce by no more than [*] the royalties otherwise due NeoGenesis
under this Section 4.3 with respect to such Licensed Product.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       12
<Page>

4.4  REMITTANCE. (a) All royalties and milestone payments required under this
Section 4 shall be payable in full in the United States in United States
Dollars, regardless of the countries in which sales are made. For the purpose of
computing Net Sales for which a currency other than United States Dollars is
received, such currency shall be converted into United States Dollars at the
simple average of all Mondays' exchange rate for buying United States Dollars
set forth in THE WALL STREET JOURNAL for the calendar quarter in which such
sales were made.

     (b) In the event that any payment due NeoGenesis under this Agreement is
not made when due, the amount due shall accrue interest beginning on the
thirtieth (30th) day following the final date on which such payment was due,
calculated at the annual rate equal to two percent (2%) above the prime interest
rate reported in the WALL STREET JOURNAL for the due date, calculated from the
due date until paid in full. Such payment when made shall be accompanied by all
interest so accrued. Said interest and the payment and acceptance thereof shall
not negate or waive the right of NeoGenesis to any other remedy, legal or
equitable, to which it may be entitled because of the delinquency of the
payment.

     (c) If at any time legal restrictions within any country in the Territory
prevent the conversion of the local currency and such currency cannot be removed
from such country such that prompt remittance by Mitsubishi of any royalties
owed by Mitsubishi to NeoGenesis in respect of sales in such country is
prevented, Mitsubishi shall use its best efforts to make payment through any
lawful means or methods that may be available as Mitsubishi shall reasonably
determine. If royalties in any country cannot be remitted within three (3)
months after the end of the relevant royalty period then Mitsubishi shall pay
NeoGenesis in the local currency of such country by deposit of the relevant
royalties sin a bank account in such country designated by NeoGenesis.

4.5  RECORDS. Mitsubishi, its Affiliates and sublicensees shall keep and
maintain for a period of at least three (3) years from the date of each payment
of royalties, records (prepared in accordance with United States Generally
Accepted Accounting Principles, consistently applied) sufficient to determine
the amounts of Net Sales and payments due under Section 4.3. Within sixty (60)
days following each March 31, June 30, September 30 and December 31 in which
payments are due under Section 4.3, Mitsubishi shall provide NeoGenesis with a
report including at least: (a) the quantities of Licensed Products that
Mitsubishi, its Affiliate(s) and sublicensee(s) sold during the preceding
quarter in each country in which Licensed Products or package products
containing Licensed Products were sold; (b) the monetary amount, in the
national currency of such country, of such sales; (c) actual Net Sales, by
country; (d) the currency conversion rate used and U.S. dollar-equivalent of
such sales; (e) the calculation of royalties thereon; and (f) the total
royalties so computed and due NeoGenesis. Such reports shall be submitted to
NeoGenesis whether or not any sales of Licensed Product have been made during
such period. Upon delivery of the report due for the period ending December 31
of each year, Mitsubishi shall also report to NeoGenesis the aggregate
royalties due NeoGenesis for the entire preceding year.

4.6  INSPECTION. Mitsubishi and its Affiliates and sublicensees shall each make
its records available for inspection by an independent certified public
accountant, appointed by NeoGenesis and reasonably acceptable to Mitsubishi,
during regular business hours at such place or places where such records are
customarily kept, upon reasonable notice from NeoGenesis, solely to verify the
accuracy of the reports and payments. Such inspection right shall not be
exercised more than once in any calendar year nor more than once with respect to
sales of Licensed Products in any given payment period. NeoGenesis agrees to
hold in strict confidence all information concerning royalty payments and
reports, and all information learned in the course of any audit or inspection,
except to the extent necessary for NeoGenesis to reveal such information in
order to enforce its rights under this Agreement or if disclosure is required by
law, regulation or judicial order. Any person or entity conducting such audit or
inspection will agree in writing with NeoGenesis to treat all records reviewed
in the course of the audit or inspection as the Confidential Information of
Mitsubishi under terms and conditions no less restrictive than the terms
contained in Section 5.2. The results of each inspection, if any, shall be
binding on both parties. NeoGenesis shall pay for such inspections, except that
in the event there is any upward adjustment in aggregate royalties payable for
any year shown by such inspection of more than five percent (5%) of the amount
paid, Mitsubishi shall pay for such inspection.

4.7  TAXES. Except for income taxes that may be assessed against NeoGenesis, all
taxes and charges that may be imposed by any government taxing authority on the
amounts paid by Mitsubishi to NeoGenesis under this Agreement shall be paid by
Mitsubishi for NeoGenesis's account. With respect to Section 4.2 and 4.3, in the
event and to the

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       13
<Page>

extent that Mitsubishi is required to pay the taxes or charges for the account
of NeoGenesis, and therefore withholds such taxes or charges from the amounts
paid to NeoGenesis under this Agreement, Mitsubishi may withhold such taxes or
charges from the amounts paid to NeoGenesis under this Agreement and Mitsubishi
shall deliver to NeoGenesis true copies of the receipts and/or returns covering
all such payments and Mitsubishi shall "gross up" NeoGenesis in respect of such
taxes so that NeoGenesis receives the full purchase price for the Products after
accounting for such withholding taxes. The parties will cooperate to minimize,
to the extent legally permissible, the tax liabilities related to this
Agreement. Notwithstanding the foregoing, such cooperation shall not cause any
adverse tax consequences to be incurred by either party which would not have
been incurred under the provisions of this Agreement, including this Section
4.7.

5.   CONFIDENTIALITY
5.1  PUBLICITY. Except as is necessary to comply with applicable laws and
regulations or to enforce their respective rights under this Agreement, or to a
party's legal or financial advisors, and except as otherwise agreed to by the
parties in writing, the parties shall: (a) keep the material terms of this
Agreement confidential; (b) agree upon the text and the exact timing of an
initial public announcement relating to the transactions contemplated by this
Agreement as soon as practicable after the Effective Date (such agreement not to
be unreasonably withheld or delayed); and (c) agree on the text and the timing
of any subsequent public announcements regarding this Agreement or the
transactions contemplated herein.

5.2  CONFIDENTIALITY. (a) Confidential Information of each party will be used by
the other party solely for the purposes permitted by this Agreement. All
Confidential Information of each party will be received and held in confidence
by the other party, subject to the provisions of this Agreement. Each party
acknowledges that it will not obtain any rights of any sort in or to the
Confidential Information of the other party as a result of such disclosure and
that any such rights must be the subject of separate written agreement(s).
Either party may only disclose the general nature, but not the specific
financial terms, of this Agreement without the prior consent of the other party;
PROVIDED that either party may provide a copy of this Agreement or disclose the
terms of this Agreement (i) to any finance provider in conjunction with a
financing transaction, if such finance provider agrees to keep this Agreement
confidential, (ii) to any legal or financial advisor of such party, or (iii) in
response to a subpoena or other validly issued administrative or judicial
process requesting disclosure of same; PROVIDED, the party that receives such
order or process provides prompt notice to the other party before making any
disclosure and permits such other party to oppose or narrow such request for
disclosure and supports any of such other party's reasonable efforts to oppose
such request (at such other party's expense) and shall disclose the terms of
this Agreement only in the event of a final judgment or administrative order
requiring such disclosure, and only to the extent necessary to comply with such
request.

     (b) Each party will restrict disclosure of the other party's Confidential
Information to those of its employees to whom it is necessary to disclose such
Confidential Information in connection with the purposes permitted under Section
5.2(a). Each party shall use reasonable efforts, including at least efforts
fully commensurate with those employed by the party for the protection of its
own Confidential Information, to protect the Confidential Information of the
other party.

     (c) Each party may at any time notify the other party that such other party
must return such party's Confidential Information. Each party hereby agrees to,
within thirty (30) days of such notification: (i) return all documents and
tangible items it or its employees or agents have received or created pursuant
to this Agreement pertaining, referring or relating to the other party's
Confidential Information; and (ii) return or certify (in a writing attested to
by a duly authorized officer of such party) destruction of all copies,
summaries, modifications or adaptations that such party or its employees or
agents have made from the materials provided by the other party.

     (d) Nothing herein shall prevent either party from disclosing all or part
of the other party's Confidential Information as necessary pursuant to the
lawful requirement of a governmental agency or when disclosure is required by
operation of law; PROVIDED that prior to any such disclosure, such party shall
use reasonable efforts to: (i) promptly notify the other party in writing of
such requirement to disclose; and (ii) cooperate fully with the other party in
protecting against any such disclosure or obtaining a protective order.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       14
<Page>

6.   REPRESENTATIONS AND WARRANTIES.
6.1  AUTHORIZATION; ENFORCEABILITY. Each of Mitsubishi and NeoGenesis represent
and warrant to the other that: (a) it is a corporation or limited liability
company, as applicable, duly organized and validly existing under the laws of
its jurisdiction of organization and has all requisite power and authority to
enter into this Agreement; (b) it is duly authorized by all requisite action to
execute, deliver and perform this Agreement and to consummate the transactions
contemplated hereby, and that the same do not conflict or cause a default with
respect to such party's obligations under any other agreement; (c) it has duly
executed and delivered this Agreement; and (d) (i) it is authorized to disclose
any and all Confidential Information made available to the other party pursuant
to this Agreement; and (ii) it shall not disclose to the other party any
information that is confidential or proprietary to itself or to a third party
unless such information is identified as Confidential Information.

6.2  NEOGENESIS PERFORMANCE. NeoGenesis hereby represents and warrants to
Mitsubishi that: (a) NeoGenesis shall perform the Program using qualified
personnel and in a good and workmanlike manner consistent with industry
standards of companies that are comparable to NeoGenesis performing similar
activities under similar circumstances; and (b) as of the Effective Date, there
is no agreement known to NeoGenesis to which it is a party and by which it is
bound that would conflict with or be breached by NeoGenesis granting Mitsubishi
the license in Section 3.1 and assigning Mitsubishi Assigned Patent Rights to
Mitsubishi in Section 3.2(d).

6.3  DISCLAIMER. (a) EXCEPT FOR THE WARRANTIES EXPRESSLY MADE IN SECTIONS
6.1-6.2, NEITHER PARTY MAKES ANY OTHER REPRESENTATION OR WARRANTY, EITHER
EXPRESS OR IMPLIED (WHETHER WRITTEN OR ORAL), INCLUDING, WITHOUT LIMITATION ANY
WARRANTY AGAINST INFRINGEMENT OF ANY THIRD PARTY PATENT OR OTHER INTELLECTUAL
PROPERTY RIGHTS, ANY WARRANTY OF MERCHANTABILITY OR ANY WARRANTY OF FITNESS FOR
A PARTICULAR PURPOSE WITH RESPECT TO THE NEOMORPH SCREENING LIBRARY, THE
NEOMORPH FOCUSED LIBRARIES, QSCD, ALL CANDIDATE COMPOUND A, ALL CANDIDATE
COMPOUND B, ALL CANDIDATE COMPOUND C, THE DESIGNATED COMPOUNDS, THE TARGETS, THE
LICENSED PRODUCTS, THE NEOGENESIS KNOW-HOW, THE MITSUBISHI KNOW-HOW, THE SCOPE,
VALIDITY OR ENFORCEABILITY OF THE NEOGENESIS PATENT RIGHTS OR THE MITSUBISHI
PATENT RIGHTS, OR SUCH PARTY'S OBLIGATIONS UNDER THIS AGREEMENT.

     (b) THE REPRESENTATIONS AND WARRANTIES OF EACH OF NEOGENESIS AND MITSUBISHI
EXTEND ONLY TO THE OTHER PARTY. NEITHER PARTY WILL BE LIABLE FOR ANY CLAIM OR
DEMAND AGAINST SUCH OTHER PARTY BY A THIRD PARTY, EXCEPT TO THE EXTENT PROVIDED
IN SECTIONS 7.2-7.3.

7.   RISK ALLOCATION
7.1  LIMITATION OF LIABILITY. EXCEPT FOR INFRINGEMENT OF THE OTHER PARTY'S
INTELLECTUAL PROPERTY RIGHTS OR BREACH OF CONFIDENTIALITY OBLIGATIONS UNDER
SECTION 5 AND EXCEPT AS OTHERWISE PROVIDED IN SECTIONS 7.2-7.3 WITH RESPECT TO
THIRD PARTY CLAIMS, THE AGGREGATE LIABILITY OF EITHER PARTY FOR DIRECT DAMAGES
ARISING OUT OF THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY SHALL BE
LIMITED TO THE AGGREGATE AMOUNT PAID TO SUCH PARTY BY THE OTHER PARTY AS OF THE
DATE SUCH CLAIM IS FINALLY RESOLVED. EXCEPT FOR INFRINGEMENT OF THE OTHER
PARTY'S INTELLECTUAL PROPERTY RIGHTS OR BREACH OF CONFIDENTIALITY OBLIGATIONS
UNDER SECTION 5 AND EXCEPT AS OTHERWISE PROVIDED IN SECTIONS 7.2-7.3 WITH
RESPECT TO THIRD PARTY CLAIMS, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE
OTHER FOR LOST PROFITS OR SAVINGS OR FOR ANY INDIRECT, INCIDENTAL,
CONSEQUENTIAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES IN CONNECTION WITH THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, HOWEVER CAUSED,
UNDER ANY THEORY OF LIABILITY.

7.2  INFRINGEMENT INDEMNIFICATION. (a) Subject to the provisions of Section 7.4,
NeoGenesis shall defend, indemnify and hold harmless Mitsubishi, its
subsidiaries, parent corporations, Affiliates, officers, directors,

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       15
<Page>

independent contractors, partners, members, employees, agents, successors and
assigns from and against any claim, suit, demand, loss, damage, expense
(including reasonable attorney's fees of indemnitee(s) and those that may be
asserted by a third party) or liability (collectively, LOSSES) imposed upon them
by any third party and arising from or related to a third party claim that (i)
use of NeoGenesis Know-How or (ii) practice of the NeoGenesis Patent Rights by
Mitsubishi in accordance with the terms of this Agreement violates or infringes
the intellectual property rights of any third party. NeoGenesis shall have no
liability or obligation to Mitsubishi under this Section 7.2(a) in the event and
to the extent that the alleged infringement is caused by: (1) modifications,
alterations, combinations or enhancements of the Designated Compounds not
created by NeoGenesis, or (2) or results from willful misconduct or negligent
acts or omissions of Mitsubishi or its Affiliates, or its or their respective
employees, officers, directors or agents.

     (b) Subject to the provisions of Section 7.4, Mitsubishi shall defend,
indemnify and hold harmless NeoGenesis, its subsidiaries, parent corporations,
Affiliates, officers, directors, independent contractors, partners,
shareholders, employees, agents, successors and assigns from and against any
Losses imposed upon them by any third party and arising from or related to a
third party claim that (i) the R&D Program or any modifications, alterations,
combinations or enhancements of the Designated Compounds; (ii) the use of the
Mitsubishi Know-How, (iii) the practice of the Mitsubishi Patent Rights, (iv)
the Designated Compound or any Licensed Product; or (vii) the Manufacture,
development, testing, Commercialization, use or other disposition of any of the
foregoing, violates or infringes the intellectual property rights of any third
party. Mitsubishi shall have no obligation or liability to NeoGenesis under this
Section 7.2(b) in the event and to the extent that the alleged infringement (1)
is covered by Section 7.2(a) or (2) results from willful misconduct or negligent
acts or omissions of NeoGenesis or its Affiliates, or its or their respective
employees, officers, directors or agents.

7.3  OTHER CLAIMS. (a) Subject to the provisions of Section 7.4, NeoGenesis will
defend, indemnify and hold harmless Mitsubishi, its subsidiaries, parent
corporations, affiliates, officers, directors, partners, members, shareholders,
employees, agents, and their successors and assigns (each, in such capacity, an
INDEMNIFIED PARTY) from and against any Losses imposed upon the Indemnified
Party(s) by any third party arising from or related to: (i) any material breach
of the NeoGenesis's representations and warranties under this Agreement; or (ii)
any negligence or intentional misconduct by NeoGenesis (or its employees, agents
or representatives) in performing its obligations under this Agreement,
including the performance of the Program. The foregoing indemnification action
shall not apply in the event and to the extent that a court of competent
jurisdiction determines that such Losses arose as a result of any Indemnified
Party's negligence, intentional misconduct or breach of this Agreement.

     (b) Subject to the provisions of Section 7.4, Mitsubishi will defend,
indemnify and hold harmless NeoGenesis, its subsidiaries, parent corporations,
affiliates, officers, directors, partners, members, shareholders, employees,
agents, and their successors and assigns (each, in such capacity Indemnified
Party) from and against any Losses imposed upon the Indemnified Party(s) by any
third party arising from or related to: (i) any material breach of Mitsubishi's
representations and warranties under this Agreement; (ii) any negligence or
intentional misconduct by Mitsubishi (or its employees, agents or
representatives) or by an Affiliate, licensee, sublicensee, distributor or agent
of Mitsubishi in performing its obligations under this Agreement, including the
performance of the R&D Program; or (iii) the labeling, packaging, package
insert, other materials or promotional claims with respect to any Licensed
Product or the development, testing, Manufacturing, Commercialization, use or
other disposition of any Licensed Product by Mitsubishi or by an Affiliate,
licensee, sublicensee, distributor or agent of Mitsubishi. The foregoing
indemnification action shall not apply in the event and to the extent that a
court of competent jurisdiction determines that such Losses arose as a result of
any Indemnified Party's negligence, intentional misconduct or breach of this
Agreement.

7.4  PROCEDURE. To receive the benefit of indemnification under Sections 7.2 or
7.3, the Indemnified Party must (a) promptly notify the party from whom
indemnification is sought (the INDEMNIFYING PARTY) in writing of a claim or
suit; PROVIDED, that failure to give such notice shall not relieve Indemnifying
Party of its indemnification obligations except where, and solely to the extent
that, such failure actually and materially prejudices the rights of Indemnifying
Party); (b) provide reasonable cooperation (at the Indemnifying Party's
expense); and (c) tender to the Indemnifying Party (and its insurer) full
authority to defend or settle the claim or suit; PROVIDED that no settlement
requiring any admission by the Indemnified Party or that imposes any obligation
on the Indemnified Party shall be made without

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       16
<Page>

the Indemnified Party's consent. Neither party has any obligation to indemnify
the other party in connection with any settlement made without the Indemnifying
Party's written consent. The Indemnified Party has the right to participate at
its own expense in the claim or suit and in selecting counsel therefor. The
Indemnified Party shall cooperate with Indemnifying Party (and its insurer), as
reasonably requested, at Indemnifying Party's cost and expense.

7.5  INDEMNIFICATION AS SOLE REMEDY. To the fullest extent permitted by law, the
indemnification provided in this Section 7, subject to the limitations set forth
herein, shall be the exclusive remedy for damages available to any Indemnified
Party.

8.   TERM AND TERMINATION
8.1  TERM. This Agreement shall take effect as the Effective Date and shall
remain in effect until the expiration date(s) specified in this Section 8.1,
unless sooner terminated in accordance with Section 8.2. The Program will remain
in effect for a period of twelve (12) months, with an option by Mitsubishi to
renew for an additional 1-year period on terms and conditions, including level
of support, that are mutually agreeable. Mitsubishi shall notify NeoGenesis
whether Mitsubishi wishes to extend the Program for additional periods, no later
than 150 days prior to termination of initial term. If the license under Section
3.1 is exercised, such license will remain in effect on a country-by-country
basis until the LATER OF: (a) the expiration of the term of the last-to-expire
of the patent rights within the NeoGenesis Patent Rights or Mitsubishi Assigned
Patent Rights or Joint Program Patent Rights, which cover the Licensed Product
in any country in which such Licensed Product is manufactured or sold or (b) [*]
following the First Commercial Sale in the last country in which sales of
Licensed Products are made (if the Licensed Products do not embody any patents
within the NeoGenesis Patent Rights or Mitsubishi Assigned Patent Rights or
Joint Program Patent Rights). Thereafter Mitsubishi's license shall be perpetual
and fully paid-up.

8.2  TERMINATION. (a) Either party may terminate the Program with thirty (30)
days notice to the other party if the other party fails to pay fees or patent
expenses due under the Agreement or commits a material breach unless the
nonpayment or breach is cured within the thirty (30)-day notice period. In
addition, NeoGenesis may suspend work pursuant to the Program with notice to
Mitsubishi if Mitsubishi fails to pay NeoGenesis any amount due NeoGenesis under
this Agreement.

     (b) Following completion of the Program, either party may terminate the
license with sixty (60) days notice if the other commits a material breach
unless the breach is cured within the sixty (60)-day notice period; PROVIDED
that such notice and cure period shall be reduced to thirty (30) days in the
case of payment obligations.

     (c) Either party shall have the right to terminate this Agreement upon
thirty (30) days notice if a Force Majeure condition has prevented performance
by the other party for more than one hundred twenty (120) consecutive days. The
parties may also terminate this Agreement at any time upon mutual written
agreement of the parties.

     (d) Mitsubishi shall have the right to terminate this Agreement with sixty
(60) days notice, if Mitsubishi reasonably determines that the conduct of the
Program has resulted in a minimal number of Candidate Compound C being
identified as potential candidates for drug development.

     (e) If Mitsubishi decides, at any time following completion of the Program
by NeoGenesis, to terminate the R&D Program or Commercialization of a Designated
Compound or a Licensed Product, Mitsubishi shall promptly notify NeoGenesis of
said decision and shall have the right to terminate this Agreement with sixty
(60) days notice. In such case, if Mitsubishi shall decide whether (1)
Mitsubishi and NeoGenesis will enter into a separate patent assignment agreement
under which Mitsubishi will assign to NeoGenesis all Mitsubishi Assigned Patent
Rights; or (2) Mitsubishi and NeoGenesis will enter into a separate license
agreement under which Mitsubishi will grant NeoGenesis an exclusive,
royalty-free license in the Territory to use all Mitsubishi Assigned Patent
Rights to research, develop, make, have made and use such Designated Compound
and to make, have made, use, distribute for sale, promote, market, offer for
sale, sell, have sold, import and export a Licensed Product containing such
Designated Compound, any such separate agreement shall contain mutually
acceptable terms. Thereafter, subject to the provisions of Section 7.4,
NeoGenesis shall defend, indemnify and hold harmless Mitsubishi, its
subsidiaries, parent corporations, Affiliates, officers, directors, independent
contractors, partners, members, employees, agents,

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       17
<Page>

successors and assigns from and against any Losses imposed upon them by any
third party and arising from or related to a third party claim that (i) such
development or Commercialization activities of NeoGenesis or its Affiliates or
sublicensees with respect to such Designated Compound or Licensed Product or the
Manufacture, development, testing, Commercialization, use or other disposition
of any of the foregoing, violates or infringes the intellectual property rights
of any third party; or (ii) any negligence or intentional misconduct by
NeoGenesis (or its employees, agents or representatives) or by an Affiliate,
licensee, sublicensee, distributor or agent of NeoGenesis in performing such
development or Commercialization activities; or (iii) the labeling, packaging,
package insert, other materials or promotional claims with respect to any such
Licensed Product or the development, testing, Manufacturing, Commercialization,
use or other disposition of any such Licensed Product by NeoGenesis or by an
Affiliate, licensee, sublicensee, distributor or agent of NeoGenesis. The
foregoing indemnification action shall not apply in the event and to the extent
that a court of competent jurisdiction determines that such Losses arose as a
result of any Mitsubishi Indemnified Party's negligence, intentional misconduct
or breach of this Agreement.

8.3  EFFECT OF TERMINATION. (a) Upon termination (including expiration) of this
Agreement: (i) NeoGenesis will terminate all tasks in an orderly manner, as soon
as practical and in accordance with a schedule agreed to by Mitsubishi and
NeoGenesis; (ii) if termination occurs prior to completion of the Program then
NeoGenesis shall deliver to Mitsubishi all materials developed through the
termination of this Agreement; (iii) Mitsubishi shall pay NeoGenesis any monies
due and owing NeoGenesis up to the time of termination, for services actually
performed (including all work-in process (if any) pursuant to the last sentence
of Item 6 or the last sentence of Item 7 of ATTACHMENT A) an amount calculated
using NeoGenesis's then-current daily charge for similar services and
deliverables, PROVIDED, such fee shall not exceed the price specified in this
Agreement and (iv) within thirty (30) days following termination (including
expiration) of this Agreement, NeoGenesis shall deliver to Mitsubishi a
reasonably-detailed written report describing the results of the research
performed up to the date of such termination.

     (b) Upon termination (including expiration) of this Agreement each party
shall return to the other party or certify in writing to the other party that it
has destroyed all documents and other tangible items it or its employees or
agents have received or created pertaining, referring or relating to the
Confidential Information of the other party.

     (c) The licenses granted to Mitsubishi by NeoGenesis under Section 3.1
shall survive any expiration or termination of the Program or this Agreement
with respect to any Designated Compound or Licensed Product for which the
applicable service fees and milestone fees and royalties have been paid (when
due in accordance with the terms of this Agreement) and Mitsubishi shall
continue to have the right to develop, have developed, make, have made, use,
distribute, offer for sale, import, export and sell Licensed Products relating
to such Designated Compounds; PROVIDED that Mitsubishi continues to pay
NeoGenesis milestone fees and royalties as required by Sections 4.2 and 4.3 and
complies with Sections 4.4-4.7. The license granted under Section 3.1 shall not
survive termination or expiration with respect to Designated Compounds or
Licensed Products for which Mitsubishi has not made payment in accordance with
this Agreement and shall immediately terminate with respect to any Designated
Compound or Licensed Product for which the applicable service fees and milestone
fees are not timely paid (should such payment become due after termination of
this Agreement or for any Licensed Product for which Mitsubishi fails to pay
NeoGenesis milestone fees and royalties as required by Sections 4.2 and 4.3 or
fails to comply with Sections 4.4-4.7. In the event the license granted to
Mitsubishi under Section 3.1 terminates for any reason, each of Mitsubishi's
sublicensees at such time shall continue to have the rights and license set
forth in their sublicense agreements, PROVIDED such sublicensee agrees in
writing that NeoGenesis is entitled to enforce all relevant provisions directly
against such sublicensee.

     (d) Except as otherwise provided herein, neither party shall be liable to
the other party for any compensation or damages by reason of termination of this
Agreement in accordance with this Section 8.

     (e) Nothing herein shall be construed to release either party of any
obligation which matured prior to the effective date of any termination.
Mitsubishi's liability for any charges, payments or expenses due to NeoGenesis
that accrued prior to the termination date shall not be extinguished by
termination, and such amounts (if not otherwise due on an earlier date) shall be
immediately due and payable on the termination date.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       18
<Page>

8.4 SURVIVAL. Sections 1, 2.6, 3.2, 3.3, 6, 7 8.1 and 8.3 shall survive any
termination or expiration of this Agreement. Section 5 shall survive any
termination or expiration of this Agreement for a period of ten (10) years after
such termination or expiration. Section 4 shall survive any termination of this
Agreement with respect to Licensed Products (including Licensed Products that
are covered by Section 3.2(d)) PROVIDED, that Section 4 shall not survive
expiration of this Agreement with respect to any Licensed Product in accordance
with the penultimate sentence of Section 8.1.

9.   GENERAL PROVISIONS.
9.1  ISSUE RESOLUTION. (a) The parties shall use their best efforts to resolve
any controversy or dispute that arises under or relates to this Agreement
through good faith discussions. The parties shall initiate such discussions
using the following procedure. Either party shall notify the other party of the
nature of the controversy or dispute, providing sufficient detail to permit the
other party to understand same (a DISPUTE NOTICE). The representatives of the
parties shall meet within 30 days after the date that the non-sending party
receives the Dispute Notice to attempt to reach an agreement about the nature of
the dispute and a resolution of the dispute. If they are unable to resolve the
dispute within 60 days after their meeting, and do not agree to extend the time
period for resolving the dispute, or if the terms and conditions of the
resolution or settlement of the dispute are breached, the dispute shall be
resolved by arbitration pursuant to the provisions of Section 9.1(b). Pending
resolution of any dispute covered by this Section 9.1, both parties will
continue their performance under this Agreement including, without limitation,
the payment of all amounts due to the other party that are not in dispute.

     (b) Except in the case of a breach of Section 3.2 or Section 5.2, any
claim, dispute, or controversy arising out of or relating to this Agreement that
is not resolved in accordance with the provisions of Section 9.1(a) within the
time period specified in Section 9.1(a) will be submitted by the parties to
arbitration in accordance with the terms of Section 9.1(b)-(d); PROVIDED, that
actions by either party seeking equitable or declaratory relief may be brought
in court without resort to any of the provisions of Section 9.1(b)-(e). This
agreement to arbitrate shall continue in full force and effect despite the
expiration, rescission or termination of this Agreement.

     (c) Any arbitration shall be conducted pursuant to the Commercial
Arbitration Rules of the International Chamber of Commerce (ICC) under the rules
then in effect for the ICC, as such rules may be modified by this Agreement or
by agreement of the parties. Any such arbitration shall be conducted in New York
City by one arbitrator. Each party irrevocably and unconditionally (i) consents
to the jurisdiction of any such proceeding and waives any objection that it may
have to personal jurisdiction or the laying of venue of any such proceeding; and
(ii) knowingly and voluntarily waives its rights to have disputes tried and
adjudicated by a judge and jury except as otherwise expressly provided herein.
The parties will cooperate with each other in causing the arbitration to be held
in as efficient and expeditious a manner as practicable. The parties will
attempt to agree upon a mutually acceptable arbitrator within 30 days of receipt
of the notice of intent to arbitrate. If the parties are unable to agree upon a
single arbitrator within such 30-day period or any extension of time which is
mutually agreed upon, three (3) arbitrators shall be used, one selected by each
party within ten (10) days after the conclusion of the 30-day period and a third
selected by the first two within ten (10) days thereafter. Unless the parties
agree otherwise, they shall be limited in their discovery to directly relevant
documents. Responses or objections to a document request shall be served twenty
(20) days after receipt of the request. The arbitrator(s) shall resolve any
discovery disputes. It is understood that the parties may (but are not required
to) submit disputes concerning any breach of Section 3.2 or Section 5.2 to
arbitration in accordance with this Section 9.1. Nothing herein shall prevent
the parties from settling any dispute by mutual agreement at any time.

     (d) The arbitrator(s) shall apply the substantive laws of New York when
construing this Agreement and attempting to resolve any dispute relating to the
transactions contemplated by this Agreement, without regard for any choice or
conflict of laws rule or principle that would result in the application of the
substantive law of any other jurisdiction. The arbitration shall be of each
party's individual claims only, and no claim of any other party shall be subject
to arbitration in such proceeding. Except as otherwise required by law, the
parties and the arbitrator(s) shall maintain as confidential all information or
documents obtained during the arbitration process, including the resolution of
the dispute.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       19
<Page>

     (e) The arbitrator(s) shall not have the authority to award exemplary or
punitive damages, and the parties expressly waive any claimed right to such
damages. The arbitrator(s) shall have the authority to award actual money
damages (with interest on unpaid amounts from the date due) and may grant
equitable relief as is just and provided by the ICC Rules, in each case except
as specifically provided to the contrary herein The costs and expenses of the
arbitration, but not the costs and expenses of the parties, shall be shared
equally by the parties. Any award rendered by the arbitrator(s) shall be final
and binding upon the parties. Judgment upon the award may be entered in any
court of competent jurisdiction. If a party fails to proceed with arbitration,
unsuccessfully challenges the arbitration award, or fails to comply with the
arbitration award, the other party is entitled to costs, including reasonable
attorneys' fees, for having to compel arbitration or defend or enforce the
award.

9.2  GOVERNING LAW. This Agreement shall be governed and construed in accordance
with the internal, substantive laws of the State of New York (except for Section
5-1401 of the New York General Obligations Law) to the exclusion of any choice
or conflict of laws rule or provision that would result in the application of
the substantive law of any other jurisdiction. Notwithstanding the foregoing,
the parties (and the arbitrators) shall use United States (Federal) patent and
copyright laws for purposes of governing and construing Sections 3.2-3.4 of this
Agreement. The United Nations Convention on Contracts for the International Sale
of Goods shall not apply to the transactions contemplated by this Agreement.

9.3  AMENDMENT AND WAIVER. No provision of or right under this Agreement shall
be deemed to have been waived by any act or acquiescence on the part of either
party, its agents or employees, but only by an instrument in writing signed by
an authorized officer of each party. No waiver by either party of any breach of
this Agreement by the other party shall be effective as to any other breach,
whether of the same or any other term or condition and whether occurring before
or after the date of such waiver.

9.4  INDEPENDENT CONTRACTORS. Each party represents that it is acting on its own
behalf as an independent contractor and is not acting as an agent for or on
behalf of any third party. This Agreement and the relations hereby established
by and between Mitsubishi and NeoGenesis do not constitute a partnership, joint
venture, franchise, agency or contract of employment. Neither party is granted,
and neither party shall exercise, the right or authority to assume or create any
obligation or responsibility on behalf of or in the name of the other party or
its Affiliates. NeoGenesis shall be solely responsible for compensating all its
personnel and for payment of all related FICA, workers' compensation,
unemployment and withholding taxes. Mitsubishi shall not provide NeoGenesis
personnel with any benefits, including but not limited to compensation for
insurance premiums, paid sick leave or retirement benefits.

9.5  ASSIGNMENT. Neither party may assign this Agreement or any of its rights
and obligations under this Agreement without the prior written consent of the
other party; PROVIDED, that either party may assign this Agreement to (a) any
Person to which such party transfers all or substantially all of its assets or
with which such party is consolidated or merged; (b) any Person that owns a
majority of the voting stock of such party; or (c) a single Person of which
such party owns a majority of the voting stock; PROVIDED, FURTHER, that in each
instance the assignee Person expressly assumes all obligations imposed on the
assigning party by this Agreement in writing and the other party is notified in
advance of such assignment.

9.6  SUCCESSORS AND ASSIGNS. This Agreement shall bind and inure to the benefit
of the parties hereto and their respective successors and permitted assigns.

9.7  NOTICES. Unless otherwise provided herein, any notice, report, payment or
document to be given by one party to the other shall be in writing and shall be
deemed given when delivered personally or mailed by certified or registered
mail, postage prepaid (such mailed notice to be effective on the date which is
three (3) business days after the date of mailing), or sent by nationally
recognized overnight courier (such notice sent by courier to be effective one
business day after it is deposited with such courier), or sent by telefax (such
notice sent by telefax to be effective when sent, if confirmed by certified or
registered mail or overnight courier as aforesaid) to the address set forth on
the signature page to this Agreement or to such other place as any party may
designate as to itself by written notice to the other party.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       20
<Page>

9.8  SEVERABILITY. In the event any provision of this Agreement shall for any
reason be held to be invalid, illegal or unenforceable in any respect, such
invalidity, illegality or unenforceability shall not affect any other term or
provision hereof. The parties agree that they will negotiate in good faith or
will permit a court or arbitrator to replace any provision hereof so held
invalid, illegal or unenforceable with a valid provision which is as similar as
possible in substance to the invalid, illegal or unenforceable provision.

9.9  CAPTIONS. Captions of the sections and subsections of this Agreement are
for reference purposes only and do not constitute terms or conditions of this
Agreement and shall not limit or affect the meaning or construction of the
terms and conditions hereof.

9.10 WORD MEANINGS. Words such as HEREIN, HEREINAFTER, HEREOF and HEREUNDER
refer to this Agreement as a whole and not merely to a section or paragraph in
which such words appear, unless the context otherwise requires. The singular
shall include the plural, and each masculine, feminine and neuter reference
shall include and refer also to the others, unless the context otherwise
requires.

9.11 ENTIRE AGREEMENT. The terms and provisions contained in this Agreement
(including the Attachments) constitute the entire understanding of the parties
with respect to the transactions and matters contemplated hereby and supersede
all previous communications, representations, agreements and understandings
relating to the subject matter hereof. No representations, inducements, promises
or agreements, whether oral or otherwise, between the parties not contained in
this Agreement shall be of any force or effect. No agreement or understanding
extending this Agreement or varying its terms (including any inconsistent terms
in any purchase order, acknowledgment or similar form) shall be binding upon
either party unless it is in a writing specifically referring to this Agreement
and signed by a duly authorized representative of the applicable party.

9.12 RULES OF CONSTRUCTION. The parties agree that they have participated
equally in the formation of this Agreement and that the language and terms of
this Agreement shall not be construed against either party by reason of the
extent to which such party or its professional advisors participated in the
preparation of this Agreement.

9.13 COUNTERPARTS. This Agreement may be executed in multiple counterparts, each
of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. In making proof of this Agreement, it shall not be
necessary to produce or account for more than one such counterpart.

9.14 FORCE MAJEURE. Except as otherwise provided in this Agreement, in the event
that a delay or failure of a party to comply with any obligation, other than a
payment obligation, created by this Agreement is caused by a Force Majeure
condition, that obligation shall be suspended during the continuance of the
Force Majeure condition.

9.15 FURTHER ASSURANCES. Each party covenants and agrees that, subsequent to the
execution and delivery of this Agreement and without any additional
consideration, it will execute and deliver any further legal instruments and
perform any acts which are or may become reasonably necessary to effectuate the
purposes of this Agreement.

IN WITNESS WHEREOF the parties have caused this Agreement to be executed ontheir
behalf by their duly authorized representatives intending it to take effect as
an instrument under seal as of the Effective Date.

NeoGenesis DRUG DISCOVERY, INC.

By /s/ ROBERT ADELMAN
   ---------------------------------
Robert Adelman
Vice President Business Development
NOTICE ADDRESS:
NeoGenesis Drug Discovery, Inc.
840 Memorial Drive
Cambridge, MA 02139
Phone:   617.868.1500
Fax:     617.868.1515

Mitsubishi-Tokyo PHARMACEUTICALS, INC.

BY /s/ AKIHIRO TOBE
   ---------------------------------
Akihiro Tobe
President of Research and Development Division
NOTICE ADDRESS:
Mitsubishi-Tokyo Pharmaceuticals, Inc.
2-6, Nihonbashi-Honcho 2-chome, Chuo-ku,
Tokyo 103-8405, Japan
Phone:  81.03.3241.4665
Fax:  81.03.3241.5187

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       21

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}]]